A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Actual Study Start Date : October 18, 2022 1.Experimental: Lebrikizumab (Cohort 1) Dosing will be based on weight. Drug: Lebrikizumab Drug: Topical corticosteroid 2.Experimental: Lebrikizumab (Cohort 2) Dosing will be based on weight. Drug: Lebrikizumab Drug: Topical corticosteroid 3.Placebo Comparator: Placebo 2021/����/29 �� ���X1��5�a�U�������Ҹ�p��,�p�W ir.aslanpharma.com/static-files/a3f199f7-f90f-43e0-8068-18a04a09edc5 2021/02/24 �p��3.52����/�� 2021/03/01 ���G1b�����ƾ� 2021/03/02 �]�P4����/�� ���p���멳�H�e,�w���Ѫ�1b�����ƾ�. �Ĥ@���p�ұN�b2023�~3��15��H�e�����B�_�h�������D ����G7*80%*92%=5.15����/�� �o�O2021/02�����Ҧ� �ӷ��ɤ��멳�}�l���D �����q�b�|��줽�G2b�ƾڡB�å]销��ӶҥH��T������D �Q���ʮɾ��b���~��! ��������T���{�ɤ~�|���n���Q���ʻ��ȡD ���q���ȴN�b15~25����/�Ѥ������|�j�D �p�Q���ʻ�40������20�U��ADR�ѥ� �C�ѳ�20�����D �n�����I���|���F�C �@�@�@�@ �M�H�e�@�ˡA�W�[�@���ꥻ�B�A ADR�q10�U�d�ѼW��20�U�d�ѡC �ثe�w�o���7�U�Ѥd��ADR �]���q�����H��奬�y�@�U�ѡ^ �i��~��12�U�Ѥd�d��ADR �p��ӥؼл�7�����C 5.6����x12�U�d�ѡת�6��7�d�U�����]�@���ҧ��^ �Ҹ�5��6���������T���ΥICSL3�d�U�������q���Q �ٷs�[�Y�]�F�����ɴڡC 2023�~1��31��l�}�{�ɪѪF�j�|���q�����i2022 �~ 12 �� 21 ��AASLAN Pharmaceuticals Limited�]�����q���^�o�X�{�ɪѪF�j�|�q���]���q�����^�N����a�ɶ� 2023 �~ 1 �� 31 ��W�� 9 �I�b 3 Temasek Avenue �|�� , Level 18 Centennial Tower, Singapore 039190 ���Ҽ{�ðu���q�L�H�U�ѪF�Mij�G �Mij 1�G (i) �@���@�����q�Mij�A�W�[���q���k�w�ѥ��G (A) �ӦۡG5,000,000 �������� 500,000,000 �Ѵ��q�ѡA�C�ѭ��ȩέ��Ȭ� 0.01 �����C (B) TO�G10,000,000 �������� 1,000,000,000 �Ѵ��q�ѡA�C�ѭ��ȩέ��Ȭ� 0.01 �����C �Mij 2�G (ii) �@���@���S�O�Mij�A���q�{������´���{�j���M�ӫh�]�Y���q���ĤQ���q�M���z����´���{�j���M�ӫh�^�����ѷs����´���{�j���M�ӫh�] �O���q���ĤQ�@���q�M���z��´���{�j���M�ӫh�^�C ����Mij 2 �������G�綠�q��´�j���M�ӫh����ij�ק�ȭ���H�U���e�G (a) �ܧq���{�j���� 7 ���A�������q�ꥻ�A�H�ϬM�W�z�k�w�ѥ����W�[�F �M (b) �C���q�g�ϥΧ�s�᪺�u�y�����q�k���N�������q�k���C �ӳq�����ƥ��@������ 99.1 ���b���B�A��ij���ĤQ�@���q�M���z�����q��´���{�j���M�ӫh���ƥ��@������ 99.2 ���b���B�A��������q�L�ޥΨ֤J����C����]�t���H�� ���� 6-K �S���q�L�ޥίǤJ���q���� F-3 �����U�n���]���s�� 333-252575�^�B���� F-3 �����U�n���]���s�� 333-254768�^�B���� S- �����U�n�� 8�]���s�� 333-252118�^�M���� S-8 �W�����U�n���]���s�� 333-263843�^�C �رi�j�C�ثe��ڪ�����ݥ�������Ӳժ����ĦA�����k���h�G EASI75 69% vs 24%(��Ӳա^�A�]������Ӳ�69%-24%=45%�^ Dupilumab 2�ӤT��.������Ӳի� ASLAN004 vs Dupilumab EASI75 45%��36%=125% ���סG�T���{�ɪ��D�n���СAASLAN004��Ĺ�LDupilumab �з����k25%��35%���ͶաC ��������������G1.���~�G���Ѫ��ƾڥ��V�C 2.�|���G�ѩR10141925 �o���ɶ�:2022/8/11 �U�� 04:00:38 �ثe�䤣�����Ҥ��L���z�ѡI (���~�G���Ѫ��ƾ�)EASI75������ASLAN004�u��Dupilumab40%�]69%/48.5�H�^�A��004�����һ��ȴN�D�`�B�D�`���C ----------------------------------------------------------------------��Q�צp�U--------------------------------------------------------------------- ���@TREK-DX���e�A���TREK-AD���Ѫ��ƾڴN���ļt�U���ʨM���F�A �f�t���~�Ĥ@�u�ɿյ��Dupilumab ��(111)�~�P���B(111�~���y�e�Q�j�Z�P��)�A �ļt�ڥ����ݭnTREK-DX���Ѫ��ƾڡA (TREK-DX���Ѫ��ƾڡA�O���ȷ�d�����Q���ʪ��B�Ϊ�) �YTREK-DX�ƾڥ������e�N�Q�֡A�ȷ�d�]�|��TREK-DX�ƾڸӦ������ȥ[�b���ʪ��̭�(�ļt�]�|�{�P)�C (���۫H�Ҧ��ļt����O���n��TREK-DX���Ѫ��ƾڥX��) �YEASI75������ASLAN004�u��Dupilumab20%�H�W�A�ļt���N�i�H���ʨȷ�d�F�A (�ڥ����ΦҼ{TREK-DX�|�Ѫ����\�Υ���)�A (TREK-DX�Ѫ����\�G���Ӫ��C��H���O�DzΫ��f�w) (TREK-DX�Ѫ����ѡG�ļt�H����[��ĵ�y�G�T�ι�H�����ϥ�Dupilumab�f�w) �ļt�u�n���DASLAN004���ġB�ڬw�ϱ��v���B�MDupilumab��(111)�~�P���B�N���F�C �ҥH�ȷ�d�̦��i��Q���ʮɶ��GTREK-AD�ƾڤ������TREK-DX�ƾڤ����e�C (�w��U��j�j�@�P�Q��) �x�ޤj Dupilumab 2b ����300mg �|�g�@�w�A��IGA0,1��2�g�@针x300mg��70%. �]Dupilumab �@�w��PK�i�W�L29�ѡC�^ ASLAN004 1A x�@�w�A600mg x6�H�]�䤤5�H��15�Ѫ���������A�^ ���q������300mg 400mg��g���w�P400mg 600mg�|�g���w , �|�g���w�ثe�٨S���Ī��W�� , �D�ԬݬݦA�� �����@�BASLAN004 2bxQ2W 0/1/2�wx300mg ���i��EASI,�ĥ|�g(��29��) **��1b 400mgxQ1Wx6�H结�G�����B �G�B2b 400mgxQ2W�� �H�W300mg/400mg EASI ��������71%. ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb Q2W�����ĥi���B�������|�W�V1b��8�g�v�������ġD �ɥR�G�Bpatents.google.com/patent/WO2020197502A1 ��10 2�H����������15�ѡB���̰���18�� 1�H����������13��, �H�W�[��B�Įľ�PK�C��15%�ϼu�D�֭p3�Ѫ�90%���Įķl���B�ȯ����10%. ASLAN004 SC�֤U�`�g���ͦ��v�j����30%(���J���骺�Ķq�̫�i�J��ު���v��30%.Dupilumab��50%) ASLSN004���������ޤ��Ķq=1mg/L=1000ng/ml ��12b�ܭ��n�BSC �U���q��PK�ͩR�ϡD IV10mg/kg: �R�ߪ`�g�B�魫�C���祴10mg.60���祴�J��ޤ��Ķq10x60=600mg 70���祴�J�Ķq700mg SC600mg:�֤U�`�g600mg ���]�i�J����Ķq50%(�ͦ��v),��L�Q����l���D 600*50%=300mg�i�J��� �B���ާA�魫�h�֡B���J�����Ķq�T�w�D �@�ӱw��SC600mg,�i�J����Ķq��300mg IV 10mg/kg �i��������29�Ѫ����i�O���T���D ��SC 600mg ����������b���i��6�H�B��5�H���15�ѡB�t�@�H���8�ѡB ��12b��dupilumab vs aslan004 ��12a�OIV dupilumab vs aslan004 2b �]�p��0/1/2�g�U�@�w�Ӥj��EASI�ܲĥ|�g��60%,�ѤU��10%~20%�i�Q��Ӱ��D�B �ڹ�Q2W*400mg���H�̱߳j�B ���ξ���魫���D �o�g�M�Q�O2020�~10��1����o---���O2021�~3��16��}�l �Ī��ʤO�Ǥ譱���q���i��S���x�� �����z�ת������A���M�Q�o���H�{���A�P Dupilumab �ۤ�AASLAN004 �i�H��{���C�� C through�A�]�� ASLAN004 �v�V IL-13Ra1�A�� Dupilumab �v�V IL-4Ra�C�b�餺�AIL-13Ra1 ���ƶq�j�j�W�L IL-4Ra ���ƶq�C �o�N����ASLAN004�ݭn���C����������A�]��ASLAN004 ���ĮľǯS�x���� ASLAN004 �P Dupliumab �ۤ�D�`���Q�A�ê��� ASLAN004 �C�뵹�Īv�����g�ʯe�f�]�p����ʥֽ����^����O ���j��ε��� 600mg �� ASLAN004 �Q�R�ߤ����� (10mg/kg) �ɡA����ܥX 100% ��������کM�b���īᤣ�� 1 �p�ɤ��������� STAT6 �C�ĤơC�o�ǮĪG�b�澯�q ASLAN004 ������W�L 29 �ѡA�����C�뵹�ĥi��O�i�H��{���C ASLAN004 �� IL-4 �M IL-13 �H�����ֳt����]�i��ɭP����ʥֽ����M�L�өʭ��ݱw�̪��g���ֳt�w�ѡC �H�W�ȨѰѦ� �ɥR�G1a 600mgx6�H�ɥR ��2�H�B�i���������28�� �b�H�U���}�W�B�i�U���ɮסD���U���Ͷչ� �g�L0/1/2�g�C�g�@�w�B���U�Ƥj�B�X�G�i�����������28�ѡD 300/400mg*Q2W �B���I�p�������������ġB�ר�O400mg. Q4W,600mg�i�u ASLAN004 1A ���d�Hx���@�w�����G�G�]���i����SCx600mgx6�H�ԲӨC�H���i�^pSTAT6 �M RO �]IL13Ra1)���w�����G�p�� 2 �� 11 �ҥܡC 0.3 mg/kg ���q���{�y�n�A��{�����������A����� 24 �p�ɡC �M�ӡA���� pSTAT6 �M������������A��í�w�W�ɡC �ۤϡA�b 1 mg/kg ���q�����U�A�b�� ASLAN004 �v�����[��� pSTAT6 �M������������������� 1 �g�]�� 8 �ѡ^�C �N���q������ 3 mg/kg �i�@�B�N�o�خĪG�����ܬ� 2 �g�]�� 15 �ѡ^�C �o���`���Ͷզb 10 mg/kg ���q�����U�~��A�䤤��{�F�j�� 4 �g�]�� 29 �ѡ^����������C ���֤U (SC) ���C�]�� 8 �� 11�^�A���G���� 75 mg ���q����b�I�� ASLAN004 �� 24 �p�ɤ���{�X�G����������ڡC �M�ӡA�o�خĪG�å�����ApSTAT6 �M������������ʤ��ᤣ�[�}�l�W�ɡC �M�ӡA�b �]SC�^150 mg ���q�����U�A�b�� ASLAN004 �v�����[��� pSTAT6 �M������������������� 1 �g�]�� 8 �ѡ^�C �N���q������ 300 �@�J�i�@�B�N�o�خĪG�����ܬ� 2 �g�]�� 15 �ѡ^�C ��� 600 mg SC ���q�]�[������������G�C PD:Pharmacodynamic �Į� 1�A55085(�s���^��70.6�]�魫������^��Full PD response to�]���������^15�ѡAPD lost by day 29) 2�B55088/65.3kg/15�ѡApartial PD to day 29 3�B55092/76.3kg/15��.PD lost by to day 29 4�B55095/82.3kg/����������8�ѡApartial PD to 15day 5�B550958/76.3kg/15�ѡApartial PD to 29day 6�B55101/68.8kg/����������15�ѡC �o�ǵ��G�i������W�[���ժ��魫�|�� PD ����ɶ����ͭt���v�T�C These results may suggest that increasing subject weight negatively impacts on PD duration. The results of the pSTAT6 and RO assays are shown in Figures 2 to 11. The results for the intravenous (IV) cohorts (Figures 2 to 6) suggest that the 0.1 mg/kg dose was able to achieve almost total receptor occupancy within 1 hour of administration of ASLAN004. However, this effect was not sustained and pSTAT6 and % free receptor levels started to rise shortly thereafter. The 0.3 mg/kg dose performed slightly better, achieving complete receptor inhibition, which lasted for about 24 hours. However, pSTAT6 and % free receptor levels again steadily rise after this. patents.google.com/patent/WO2020197502A1 �Y��ASLAN004 1a���d�H��Ʊ��� �H�U004����}�����B�����I�D IGA0,1/IEASI90�����Ĥ���x���F���D �ثe�Y���Ѫ���IGA0,1�������Ʋz�Q�B�̥i��X�{���D���N�i��b���Q4W�{�ɡD Q2W���I�D�`�p�D �ȷ�d�S�n�ѥ[��ڷ|ij�ͪ��X�@�|ij �n�b�����|ij�W���U�P�z�h�|���A�гX�ݦ��챵�C �� 12 ���~�� LifeSci �X�@�٦���~��J���� ASLAN Pharmaceuticals �z�h�N�� 2023 �~ 1 �� 10 ��b�ª��s�ѥ[�������ʡA�ûP���c�����|��@��@�|ij�C �Yģ�]�O�|���M�ļt�|�����v�N��ñ�q���v�X���γ\�V�O�Բӯu�ꪺ�ƾڤ~�൹�X�w�����Y��������05/06���q���i����36�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A111/12/06�H����Ѫ��ƾڡC ���q��W���ƾڤF�A�ӥB�ҩ��@TREK-DX ���\�����v�ܰ��C (�Y���~4��TREK-AD�Ѫ��ƾڥ��V�����|�ܤj�A�~�|��@TREK-DX) (�ļt���DTREK-AD�Ѫ��ƾڥ��V�Ӥ�����??�n���TREK-DX�Ѫ��ƾڥ��V�A�~�ӥ[������???�褣��) �b���@TREK-AD�����פ��ߡA�������ӧ@TREK-DX�A�Y�٥h�A�䦬�פ��ߪ��ɶ�??? ���ӬO���ƾ��ҩ������|���o�����{�ɷ|���\�~�W���� �ӥB�{�ɪ�����O�������B��U ?�|�O��b���R�a?�٬O�s�����D ���٬O���[�ݫݳo������j�A�j�P�h�ä��q�u�Q�����b0.5�H�W�A���H�W���W�L1���A��2023/3/26��A�W��A�H�}���Ȭw���v��ҡC�Ӥj ����ѥ��j���A�L�]�S��ۤ����A ���Ѥj�^�ɥL��۶^�A�{�b�ѻ��@���r ���v�C�I�A �L�̬һ⦳���q�~���A�������������O�q���A�o�O�L�̬��ۤv�Τ��q�������Ʊ� �C�����q�����T���ΰѥ[��ڷ|ij������A �ѻ��ҬO�ϦV�����A��������Ū�������P�A�O�H�O�ѡA ���M�ڤ]��ȷ�d�ܥ������Q�ѯu���O�D�Ԥ��o ���Ѽɶ^�A�p���ѳ����n �ۤϦa��ı�o�ȷ�d���T�ꤽ�i�s�D�O�n�� �ܤ֤��q�٦��b�V�O�A�Ʊ椴�b�S�O�@�˱��� �ȷ�d���q�ť����n�T�� ���Ѫѻ��@�w���� ���Ѥ��ҥ~�ź٤w�n����s�Ĥ@��f�H �{�b�ѻ�����10%�H�W �u�O�з�韮�榬�ΪѡA�Φn�κ� �ȴ����s�Ħ������q 2022 �~ 12 �� 15 ��P���|�ߤW 8:00�P7 �����\Ū �ȴ����s�Ħ������q �b Dupilumab ���g�窺�S���ʥ֪��w�� (TREK-DX) ��s���ϥ� Eblasakimab ������N�b�X�G�S���w���v����ܪ��w�̸s�餤���� eblasakimab �Ӭ�s�N�b�_���۶� 75 �W�w�̡A�w�p�N�b 2024 �~�Ĥ@�u����o���u���G ��s����R���A�蠟�e���i���{���]�D�S���v�T �Ӧ� TREK-DX �M TREK-AD ���ƾڥi�H��� eblasakimab �Ω�ͪ��Ǫ�v�M���g�窺 AD �w�� ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients The study will enroll 75 patients in North America with topline results expected in the first quarter of 2024 Study is fully funded with no impact on previously reported cash runway Data from TREK-DX and TREK-AD could support the use of eblasakimab for both biologic naïve and experienced AD patients 2b �{�� 400mg xQ2W�A����2b �ھ�ASLAN004 1b 400mg x8�gx�@�w���g�A�@8�w�AN=6 (2021/03/1������ơ^ ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb 1.����EASI���T⋯�]lb=2b) ⋯⋯�@�@�@ 300mg �b���d�H1a�{�ɲ�8��IL13Ra1=0%�A��15��=30%�]���p��������O逹��13�ѡ^ �h2b�{��400mg��������i�Ѳ�0�ѡ��27�P5�ѡA��G����IL13Ra1�i�O��0%���A�C ���סG2b ��29�Ѫ����ġAEASI�������T���p�u��3%���k�A�i�F��62%�C ⋯⋯⋯⋯ �Ĥ��g�]��43�ѡ^73%⋯ 2.��L�������ġG TRAC���T�G �|���G�ѩR10141925 �o���ɶ�:2022/11/12 �U�� 07:52:46�� 5764 �g�^�� �@�@�@�@ Dupilumab 2a N=110 QWx12�g Vs Lebrikizumab 2b Q2Wx16�gN��75:52 1�AEASI50 Dupilumab �i�P�ɪ������йvIL4/IL13�A�ҥH�b�Ĥ��gEASI50�N�F���I85%��Lebrikizumab�u�����IL13�γ���lL4�ҥH����ĤQ�G�g�~�F81%���I�C �G�AEASI75 �ĥ|�g 35%//30% �T�BIGA 0,1 �ĥ|�g 18%//18% www.nejm.org/doi/10.1056/NEJMoa1314768 www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=7142380_jamadermatol-156-411-g002.jpg �ϤG�����G Lebrikizumab ASLAN004 1b mITT �U�����Ь��b�Ĥ��㤻�g���̨θ��I�C�B��赢�LLebrikizumab ��16�g���ƾڡC �H�W�ɥR�����C ��Lebrikizumab�]�L�k�����ʪ�IL4/IL13�G�^ ���n���г̨θ��I�j�h�X�{���12��16�g�C www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417deLebrikizuma 2�ӤT���{��,�C��g���Ͷչ�(2022/03/30)---Almirall ���q(�ڬw�ϾP�⤽�q) �D�n����:EASI75//IGA0,1 �̫�p���q�ҹw������(IGA 0,1)8% ����Dupilumab 2�g�зǪv�����|��. �ؼл��p����:4~7����/�Ѿ��|�� �x�j��|�ֽ���D�����a��@�����ײ���ʥֽ����w�̡@�`����5�j�g���x�j��|�ֽ���D�����a����v���ܡA�����ײ���ʥֽ����w�̦�5�j�g���A�������ܦ��u��g���ڡv�C 1. �o�G��s���i���X6���H�W�����ױw�ֽ̥��b�@�Ѥ��o�o�W�L12�p�ɡA����o�o��57%�w�̷P���g�C ���F�H�W��5�I�~�A�ֽ��|�y��β�´�G���w�̷P�������A�Q�n�B���ۤv���w�����קK��L�H���鱵IJ�C �x�W����ʥֽ����w�̡@�ͬ��~��լd ���a����v���ɡA���~�w��x�W����ʥֽ����w�̶i�檺�ͬ��~��լd�]�o�{�������G�A���R150�즨�H�w�̪��X�ݫ�A�o�{����ʥֽ����Y���v�T�U�ͬ����V�A�p��`���ʡB�u�@�DzߡB�H�����Y���A�f�p�V�Y���B�ͬ��~��V�t�C�Ҧ��w�̪��ίv�~�賣���n�A�������U�J�Ϊ���ҬO��H��1.5��12�A�B�u�@�Ͳ��O�]���v�T�A4�W�w�̴N��1�W�S�u�@�A���~�v�����ꥭ����7���C�����S���J�A75%�w���ٷ|�����Dz����k�B���d���~����L��k�A��O�[���w�̪��t��C �����ײ���ʥֽ����v���T���� ���a����v���ܡA�����ײ���ʥֽ����v�����T�����F�Ĥ@���q�`�|����ij�w�̨ϥΨŲG�B�O�㾯�Υ~�����T�J�Ī��M�ܲ�´�i�Ī��A��52%���w�̤����N�~�����T�J��g������ĪG�A�B�����ϥΫ�|���ϥֽ��������Ƨ@�ΡC �ĤG���q�`�|�ϥΧK�̧���ĻI�ηӥ��v������k�A�e�̷|�y���ֽ����`���P�P�k�o�A��40%���w�̷P�즳�Ƨ@�Τ�63%�w�̤����N�K�̧���ĻI��g������ĪG�F��̦�60%���w�̤����N�ӥ��v������ĪG�C �ĤT���h�ϥΤF�K�̽ո`���ӱ���o���ιL�Ӥ����A�������ϥΧK����i��|�v�T�x�B�ǥ\��A���@�w������G�ˬd�C�b�ϥΧK�̽ո`�����w�̤��A����53.4%����ҡA�f�p�Q��v�k��������}�C��8��������ʥֽ����w�̹��v���ä����N�A��4���w�̧�L5�ӥH�W��v�C�ӳ̷s���ͪ��s�����M���ġA���@�w�ݭn28000�A��w�̨ӻ��O�@�����p���t��C ��g���ڡG�{�Ѥ����ײ���ʥֽ��� - Heho���d 2022Q3 VS 2021Q1(�]�P4����/��) �έp 21,750�d�� VS 27,000 �d�� ��W: 5,250�d��, �䤤�R�W�̦h���O : whalewisdom.com/stock/asln �@.2022//Q3 ������c��ASLN ���� TANG CAPITAL MANAGEMENT LLC 5,654,925 �X�p�� 21,750,000 �G.�|���G�ѩR10141925 �o���ɶ�:2021/5/19 �U�� 03:50:19�� 4214 �g�^�� whalewisdom.com/stock/asln RTW INVESTMENTS, LP 3,250,000 LUMINUS MANAGEMENT LLC 1,753,800 SABBY MANAGEMENT, LLC 817,165 �X�p ��27,000,000 , 38.5%(27,000/70,000) �V�u�����o�@�u�O��F�v�I �ֽ�����v�ФT�ۤ��A�}�֬y�w �� �v�� 2022�~12��11�� �g�� �U��2:00 �y�s�D���O�̳��v�͡��x�_���� �o�o�A�O�A��F�I�o�O�V�u�ֽ���E���̱`ť�쪺��ܡA���M��|�ֽ�����v�I�ɽ����N���v�@�W5���k���]����ʥֽ����o�@�A��ߤ������o�A�L�k�J�v�A���u���}�֬y��A�ƦܥX�{�ˤf�o���B�y�w���ӵ߷P�V�����p�A���������s�¶ˤf�C��v�����A���ɥi�H�[�j�O�áB�קK��E�B�����L�ӭ쬰���@��h�C ����ʥֽ����W���A�ꤺ���E�[��A���֤p�B�ͱ`�]�k�o���@�A�L�k��o�R���ίv�A�믫���٪����p�U�A�i�Ӽv�T��դѪ������B�Dzߵ����ʡA�t�~�A�a���]�`�P���캡�����h �I�ɽ�A����ʥֽ����O�x�W�`�����ֽ��e�f�A�O�@�ئh��]��Ǫ��o���e�f�A�D�n�O�ѥ��ѩʧK�̽ո`���`�Ϊ��֤��b�ձ����թҤް_�C�ھڲέp�A�x�W���W�L200�U�W�w�̡A�ܦh�H�q������ɴ��N�}�l�o�f�A���F�Y���k�o�a�Ӫ����A���~�A�����B�C�l�Τ��еo�@�y�����ֽ��a���ơA�]�����v�T��w�̦۫H�B����ΤH�����Y�o�i�A���_�o���S�ʤ������f��v�����h���ݡA�Ʀܲ������O�P�t�������C ���E���N�����w�̦]�ⳡ���j���f�_�Ӥ����P�H����A���[�U�Ӻt�ܬ������ê�A�[�W������A�סA�b�D�ǤΨD¾�L�{���W�W�I���C �I�ɽ���X�A����ʥֽ������Φ��M��j�]�������A�����O�u���̻֫ٯʳ��v���O�A�ֻE�J�կʳ��B���g�Q�i���������F�䦸�O�u�K�̲ӭM�L�פ����v�A���S�w�K�̲ӭM�H��ӭM�L���ơA�N�|�y���ֽ��o���A�Φ��x���B�o�o�B��h���{�ɪ��{�C �ȱo�`�N���O�A�I�ɽ廡�A����ʥֽ������f�_�����|�H�ۦ~�֦Ӧ��Ҥ��P�A�b����Υ����ɴ��A�f�_�D�n�����b�y�B��y�ν��\�F�~�����j���p�ġA�h�b�|���s���B�X�{�C�ʭa�~�Ưf�_�F��F�C�֦~�Φ��H�A�ֳ����f�w�i��|�n�ण�A�_�o�A���j�h�|�����Χ��ܫ��A�A�Ʀ��ܦ��Y���������f�_�Υ����ʻ��ׯf�_�C �I�ɽ��ij�A�������w���N�屵���v���A�o�f�ɥt�i���q���šB�q���}�l�A�çQ�Ψ�L�ƪ��ಾ�`�N�O�H�K��ˡA���`�h�`�N�O�áB�קK��E�λ����L�ӭ쵥���@��h�F�ܩ�ൣ�ΫC�֦~�A�b�߲z����������o�S�O�`�N�A���O�C�K�����J�{�A�άO�D�ǡB�dzƦҸչL�{�������O�����i��IJ�o�A���H�Ī�����B�ﵽ�f�p�~�A���n�ɤ]�i�M�D�߲z�Ө�U�A�άO���A�X�覡��o�������O�A���O�A�B�ʡB�W����гy�ʪ����ʩΥ[�J�P��������ɤ߱����C �Ӥ��ӷ��G���M��| �ѧN �i�峹����е����X�B�j -~B/aD0yMDA7dz02NzA7YXBwaWQ9eXRhY2h5b24-/s.yimg.com/os/creatr-uploaded-images/2022-12/3dbc4bf0-76d7-11ed-bbfc-88e626aa2a99 Lebrikizumab �G�u(��Dupilumab�ϥθg��)��-����AD �T���{��120�H,�Y�N�}�l.�w�p12�Ӥ맹��.�w���G16�Ӭ��ꦬ�פ���: ASLAN004 �G�u(��Dupilumab�ϥθg��)��-����AD ,�G��, �w�p12�멳�����Ĥ@�ө۶�. �H�W�G���{�ɴX�G�P�ɩl --------------------------------------- clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3 ���j�Bwhalewisdom.com/stock/asln ����1000�d�Ѫ��j�ѪF�k�H��7�Ӥ��q�D �L�̪��g�z�H�|�MASLN���q���H�k�� ���|����儍! ��p���Ѫ���b�L���T�ƾڥi�Ѥ��u! �o�a���q�C���ѥ[��ڷ|ij��A�Ϊ̤����Ѫ��T���A�q�S�n�Ƶo�L�A�ѻ��q�����������A���O��^�άO�w�^����^�A�Pı�O�Ӫ��Y���q�ACEO �N�O�֥]�նR�Ž�Ū��A 004 2b��B�������ƾڦp�G�����A ��l�j�ѪF�@�w�|�����D�A�ѻ��S�b���v���C�ɡA�j�ѪF�̲@�L�@���A�L�����@�L�ʧ@�A�N�O�綠�q�@�L�H�ߡA �ڹ綠�q�]����Ʊ�A�N���R�ֳz�A��������̡A Aslan004 2b �q���δ���G�̾�Dupilumab��Lebrikizumab 2b,ASLAN004 1b1.400mg/Q2W EASI75 69% IGA0,1 53% 2.400mg/Q4W IGA0,1���IJq�� 1.05/06���i����36�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A111/12/06�H����Ѫ��ƾڡC 2.06/28���i����39�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A112/01/28�H����Ѫ��ƾڡC 3.07/13���i����42�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A112/02/13�H����Ѫ��ƾڡC 4.07/15���i����43�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A112/02/15�H����Ѫ��ƾڡC 5.08/01���i����45�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A112/03/01�H����Ѫ��ƾڡC 6.08/23���i����65�ө۶�(����)���ߡA�[2�Ӥ�۶�(�z��)�A�[4�Ӥ�v��(����)�A�[1�Ӥ�ƾھ�z�A112/03/23�H����Ѫ��ƾڡC ���~5��6��A���q���i�w�}�F36�ө۶Ҥ���(�W�L�������S�һݱ���)�A ���]��2�Ӥ�ө۶�(�z��)�A�Y7��6��}�l�v���C �A��4�Ӥ�v���A�h11��6�骺16�g�v�������C �A1�Ӥ��ƾ�z�A�]�N�O����(12��6��)�H��i�H���S�����ƾڡC �U��i�H�}�l�[��ѻ������{�F�C www.clinicaltrials.gov/ct2/show/results/NCT03443024 125mg-Q4W//250mg-Q4W//250mg-Q2W//��Ӳ� 1.EASI 75�]%�^ 2.IGA0,1�]%�^ �C�|�g�@�w�@250mg vs �C2�g�@�w250mg Lebrikizumab 2b ���|�g�@�w�bEASI75�����Ĭ��G�g�@�w93%�]�e16�g�v���^ �@�@�@Lebrikizumab ph3 17��52�g�v��.�b4�g��2�gEASI75&IGA0,1���Įt���h�C �G�BDupilumab 2b �|�g�@�w vs �G�g�@�w www.clinicaltrials.gov/ct2/show/results/NCT01859988 300mg-Q4W//300mgQ-2W//��v �T�AASLAN004 2b �|�g�@�w vs �G�g�@�w �����Įt���H�H�H �]�\����W�zLebrikizumab 2b��Dupilumab 2b �|�gVs �G�g���Įt�� �bEASI75 �t��93% �H�ڭ̪��{�ɸg��A 3.EASI-90(�ﵽ�E��)�|ı�o�X�G�n�F�A�֧���ͷ����b���C�Y�N�v���ĪG�q�ơG www.dr-skin.com.tw/health/view/240 ASLN ���q���ӥu�����Ѫ����ƾڡC �p��i�j�Ҧ��A�ܤ֦���50%����16�g�v���C �|���G�ѩR10141925 �o���ɶ�:2022/12/2 �W�� 06:32:10�Q�߶Ȩѿ����ɡD�i�W���U���D��L�p11��²�����e�D�D���H�ݨ�ASLAN004�T���dzơB���G�N�O400�H���{�� �����G 2.���~5��6��A���q���i�w�}�F36�ө۶Ҥ��ߡA���]��2�Ӥ�ө۶�(�z��)�A�Y7��6��}�l�v���C�A��4�Ӥ�v���A�h11��6�骺16�g�v�������C�A1�Ӥ��ƾ�z�A (�z���h�w���D�����ƾڤ��e�A�D���H�~�|�ݤT���dzư��D) �ȷ�d004�T���A��400�H�{�ɰ��dz� �O�_�N��2���{�ɤw�L���D�� �i��|��2���������i�ܡA�ѨM�ѻ������C��1�����M�� ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference�Q�߶Ȩѿ����ɡD�i�W���U���D �D�u�H�ݨ�ASLAN004�T���dzơB ���}�l��,�S�ťh�H���q��5��6�餽���ֿn36�Ӧ��פ��ߦ���(�W�L�������i���S�һݭn��)�A ���Y��6��20�馬������̨ö}�l�v���A �g4�Ӥ�v����Y�O10��20��A �A1�Ӥ��ƾ�z�Y�O11��20��C �Q��(11/21)���q���i�N�b�ì��ѥ[�����O���|ij(11/29~12/1)�C (���n���ݤӲ`�A�]�u��CEO�h) �a��004�����ƾڡA�άO���ƾڤ]�n�A���������R�v�M�a���A�{�ҡA�ѷ�~�����|�X�Y�ѡCASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to participate in a fireside chat at the Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 8:30am ET. The conference will be held from November 29 to December 1, 2022, in-person at the Lotte New York Palace Hotel, New York, NY. A replay of the fireside chat will be made available on the Investor Relations section of ASLAN��s website and can be accessed directly at this link. Management will be available for one-on-one meetings with investors throughout the conference. Please contact your representative at Piper Sandler to schedule a meeting. ASLAN 2b����(�ɥR)��0�� EASI28 ��21�� ����组����EASI=14��(��50%�^ ���组����EASI=25��(��12%) �[��G�C www.nejm.org/doi/full/10.1056/nejmoa1610020 ��Ӳեu���w衞�����w�̡C �b�ĤT�g�����Ĭ�12��15%�A�������U����12�g33%�C�]���w��衞���̥禳AD��¡��O�A��������20%��18%�^ �ӥ�Dupilumab���դ��ިC�g�@�w�ΤG�w�A�b�ĤT�g���Ĥw�U����45��50%EASI �b�ĤT�g�ɥ�Dupilumab�۹�w衞���կf����35%�j�A�ҥH��¡��O�z���j��w衞���աC ASLAN004 2b�e�T���i��������IL/IL4���21��A���ᦳ22��27��i��L��������p�A��������w衞���ժ���¡��O�i��C �[��T�C �pASLN004�����Z�o��lbX8�g�v�� ��ĤK�g����凖�A��7��11�g�����w�A���O���C������TRAC�C ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c �H�W�O�[��α��z�ӨӡC��ڤ���2b�Ѫ��誾�C �Ϥ@�ADupilumab ���� EASI50 75mg vs 150mg vs300mg vs��Ӳ� x�C�g�@�wx4�g �ѹϤ@�i�[���A��30�Ѫ����� 300mg >150mg>75mg>��Ӳ� �䤤300mg/150mg �b��15�骺p�ȴN�p��0�P05 �έp�W������t���C 75mg/150mg �C�g���ĦH��300mg���ܡA���q�����A�L�k�����ʪ�I4/IL13��T�ǻ��C Lebrikizumab �]���������p�A�����v¡��52�g�BIGA0�A1�|�A�W�[4%��5%�C ASLAN004 0/7/14��U�@�w.�i���������21��AEASI50 �i�F��55%�A ��4�w�b28�饴�w��A��ӳt�״N���ӫ�_�C �ҥH004 2b ��16�gX9�wx2�g�@�w���ġA���p>=1b ��mITT 8�g�������ӬO�X�z�����C �@�@.�@.�@�@�@�@�@�@�@�@�@�@�@�@ EASI 75=73%~81% vs 24% (�M��Ӳծt�� 49%��57%�^vs Dupilumab 2b 61% ������Ӳծt���A�����u��Dupilumab 2b 30%�H�W�����|�A���Ī���f�A�Ī��]JAK����G缐�Ī��^���i��ʤj�C �H�W�ӤH�����C �t�~Q2 ������}�������ASLN ��֬�1400�d��ADR �̤j�ѪFTang �ꥻ��ꤽ�q���p�[�X100�d��ADR �s�[�Y�H�������Ѥ��ܡC whalewisdom.com/stock/asln ASLAN004 �C�g�@�w�A�e8�gEASI�U�����ijt�שMDupilumab�۪�C �@�@�@�@ Dupilumab 2a N=110 QWx12�g Vs Lebrikizumab 2b Q2Wx16�gN��75:52 1�AEASI50 Dupilumab �i�P�ɪ������йvIL4/IL13�A�ҥH�b�Ĥ��gEASI50�N�F���I85%��Lebrikizumab�u�����IL13�γ���lL4�ҥH����ĤQ�G�g�~�F81%���I�C �G�AEASI75 �ĥ|�g 35%//30% �T�BIGA 0,1 �ĥ|�g 18%//18% www.nejm.org/doi/10.1056/NEJMoa1314768 www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=7142380_jamadermatol-156-411-g002.jpg �ϤG�����G Lebrikizumab �T�BDupilumab �T�� vs ASLAN004 1b mITT 600mg �U�g����EASI�U���T�e8�g�۪�C�]�N�����۷��P�ɪ���IL4//IL13��T���IJv) www.nejm.org/doi/full/10.1056/nejmoa1610020 ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c �۶үf�H���{�p�i�� �άO�_�w�۶ҧ��� �����ҵL���� 2b���������ƾڤ������� �֨ӭӥ��V�������ƾڡA�^�}�j�a������A�����c�k�H�Ӥ��Τ��� !²���X§�Ӥ��q�V FDA ���� BLA �Ω�v���S���ʥ֪��Ī�02-11-2022 ���L ��h����o�ӬG�� ����s�ĥ��Y§�� (Eli Lilly) �w�V���ꭹ�~�ī~�ʷ��z�� (FDA) ����F lebrikizumab ���ͪ��s�~�\�i�ӽ� (BLA)�Alebrikizumab �O�@�إΩ�v�����צܭ��ׯS���ʥ֪� (AD) ����s�ʥղӭM���� (IL)-13 ���s��. AD �O�@�� IL-13 �D�ɯe�f�A�䤤 IL-13 �ɭP�ֽ��̻٥\���ê�B��o�B�ֽ��W�p�M�P�V���P�ʡC Lebrikizumab ���b�H���˩M�O�B�C�����t�v�M���ĤO���X IL-13�A�H���� IL-13 ���ͪ��Ǯ����C �Ӵ���o��F ADvocate 1 �M ADvocate 2 16 �P�M 52 �g���G�H�� ADhere 16 �g���G������A�o�ǵ��G�O�H���B�����B�w������ӡB����աB���y�BIII ������ lebrikizumab �@����@���k�ûP�з��@�z�~�Υֽ����T�J�p�X�Ω�C�֦~�M���H�]12 ���ΥH�W�^�����ĩM�w���ʪ���s�C �ھ� GlobalData ���ƾڡA�S���ʥ֪� (AD) ���������ȹw�p�N�q 2020 �~�� 64 �������W���� 2030 �~�� 7 �ӥD�n������ 168 �������A�ƦX�~�W���v (CAGR) �� 10.1%�C BRIEF�XLilly submits BLA to FDA for atopic dermatitis med MORE ON THIS STORY Lilly and Almirall��s lebrikizumab impresses a year in to eczema trial Lebrikizumab has significant impact on atopic dermatitis severity OTHER STORIES OF INTEREST AI firm Insilico could pocket $1.2 billion in Sanofi tie-up Broader label to support greater US growth for Libtayo RELATED COMPANIES AD is an IL-13 dominant disease in which IL-13 drives skin barrier dysfunction, itch, skin thickening and susceptibility to infection. Lebrikizumab is designed to bind IL-13 with high affinity, slow disassociation rate and high potency to inhibit the biological effects of IL-13. The submission is supported by the ADvocate 1 and ADvocate 2 16-week and 52-week results, as well as the ADhere 16-week results, which are randomized, double-blind, placebo-controlled, parallel-group, global, Phase III studies that evaluated the efficacy and safety of lebrikizumab as a monotherapy and in combination with standard-of-care topical corticosteroids in adolescents and adults (12 years of age or older). The atopic dermatitis (AD) market is expected to grow from a value of $6.4 billion in 2020 to $16.8 billion in 2030 in the seven major markets at a compound annual growth rate (CAGR) of 10.1%, according to GlobalData. �����@�u�ظ����{�ɼƾڹF�� ���~��ӽЬ������d����x�_2022/11/09 ���� (4162-TW) �� (19) �餽�i�A�X�U�ظ����s�Ħw��o (ONIVYDE) ���զX���k�A�v���@�u�ظ��������y�ϯé��{�ɸ���A�D�n�P���n�������Ч��F������{�ɷN�q�A����N�i�@�B��z�ƾڡA�̧֩��~��V���� FDA ���X���ҥӽСC �������ܡA���{�ɸ���O�ѱ��v�X�@��� IPSEN �Ӱ���A�N�w��o�f�t�����ī~ Oxaliplatin (OX)�B�~�F���� 5 Fluorouracil (5-FU)�B�Ѭr�� Leucovorin(LV) ���զX���k�A�åH�ثe�@�u�ظ����зDzզX���k�@�������ӲաA����H���ಾ�ʯظ��ɺ����w�̡A�@ 770 �H�C �ھڸ��絲�G��ܡA�D�n�������Ъ��`�s���� (OS)�A�w��o�զX���k����u��зDzզX���k�B���n�������Ф����L�c�Ʀs���ɶ��]����۪��ﵽ�F�w���ʤ譱�P�L�h�{�ɤ@ / �G���ƾڹp�P�C �������ܡA�X�@�٦� IPSEN �N�|�⦹�����絲�G�A�f�t�L�h�w��o���ֳt�f�d���A�V���� FDA ����A���g�������ӽСA�̧֩��~�짹���A���ӦA����V�ڬw�B�饻�B�x�W���a�ϴ��X���A�ݨ��o���ҫ�N�|��o���{�O���C �ڲέp�A���y�C�~�E�_�X 50 �U�W�ظ��ɺ����w�̡A����C�~�h�� 6 �U�H�A�ѩ����q�S���S�w�g���A�q�`�e�f�X���쨭���L�����~�|�Q�o�{�A�ثe���E�_�X���w�̤��A���� 2 �����H�s�����W�L�@�~�C �ڤ]ı�o�}�����O���|ij,������n�aCBO�h???��ӬO......Mr Stephen Doyle, CBO CBO�}�l�����v�B���ʤF!�B ASLAN PHARMACEUTICALS LIMITED Tue, November 8, 2022 at 8:00 PM�P1 min read ASLAN PHARMACEUTICALS LIMITED ASLAN PHARMACEUTICALS LIMITED SAN MATEO, Calif. and SINGAPORE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, and Mr Stephen Doyle, CBO will be participating in one-on-one meetings at the Jefferies London Healthcare Conference from November 15 to 17, 2022. The conference will be held in-person at the Waldorf Hilton hotel in London. Please contact your Jefferies representative to request a one-on-one meeting with management. 2022�~Q3�]���X�linvestor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2022-financial-and-operating ���~�e�T�u�禬�w�W�L2021���~�A���~�P�����87�������C���~��110�������C Dupixent /Dupilumab ���:�ʸU���� 2022 2021 2020 2019 2018 2017 www.taiwan-pharma.org.tw/weekly/2166/2166-5-3.htm Janus Kinases�]JAKs�^�ݲӭM���ï��A�ñN�ӭM���W���T���ǥX�A�b�ǻ����|���AJAKs�|�P�ϰT���ǾɻP������Ʀ]�l(STATs)�C�ĤƤά��ơA�ո`�ӭM��������A�]�A��]���{�A�v�T�y��ӭM�B��P�K�̲ӭM�\��CJAK������йv�X���ܭ���f�Ī��]targeted synthetic DMARDs, tsDMARDs�^�O��~�ӷs�o�i���Ī����O�A�g��JAKs�ո`�ӭM�T���ǻ����|�A����STATs�C�ĤƻP���ơA�i�ӧ���o�������A���{���Ī��L�k�F��v���ؼЪ��f�H�v���a�ӷs��ܡC�۸���ͪ��s�����ݰw���A�����ī~���S�⬰�f�A�뤩�A�f�H�ϥΧ�K�Q�C��ij�v���ɾ��PboDMARDs�ۦ��A�Ω�csDMARDs�X�֪v���ᤴ�����ﵽ�ɡA���ثe���ޤ��u����ij�ϥ�boDMARDs�A���F�v���ؼФ~�Ҽ{�ϥ�tsDMARDs�C�ثe�v�����ޤ���������JAK���tofacitinib�Bbaricitinib�ҫD��ܩʧ���JAK-1�A�䤤�P�ɧ���JAK-2�B3�|�ɭP�y��F�ӭM�]hematopoietic cell)�B����y�ͦ����]erythropoietin�^�����n�Ͳz����T���ǻ��Q���_�A�i�@�B�y�������Ƨ@�ΡC ��ܩ�JAK-1����z�L�M�@�ʧ���A������C�]����JAK-2�B3�ұa�Ӫ��Ƨ@�ΡA���ꭹ�~�Ī��z���]FDA�^��2019�~8��16��̾�Fleischmann ���H�o�������絲�G�A�֭��ܩ�JAK-1��� upadacitinib�]UPA�^�Ω�v�������צ��~RA�f�H�C���H�����ĤT���w������Ӹ��笰��26�g�A�@����449����ժ̡A�ұw�����ʩ�RA�B�ϥ�MTXí�w�v���ܤ֤T�Ӥ�H�W�A�����ϥιL��LboDMARDs��tsDMRADs�W�L�T�Ӥ�A�B�b�v���ᤴ�����e�f���ʡC���ժ̸g�H���������T�աG�C��f�AUPA 15 mg�B�C��g�֤U�`�gadalimumab�]ADA�^40 mg�H�Φw�����աA�U�լ��~��ϥέ�B�褧í�w���qMTX�C���絲�G��ܡA�b�� 12 �g�������A�P�w�����դ���A�F��~�Ȥ�IJ�h���`�Ƨﵽ�FACR20�]American College of Rheumatology 20% improvement criteria�^���f�H��v�A����UPA 15 mg�P�w�����դ��O��71% �P 36%�]p��0.001)�A�B�b26�g���������w�����ըΪ����{�F�P ADA �դ���A�b��26�g�F��~�Ȥ�IJ�h���`�Ƨﵽ�F50%�]ACR50�^���f�H��v�A����UPA 15 mg�P ADA �դ��O��54% �P 42%�]p��0.001)�A�ҹF�έp�W��ۮt���C�w���ʤ譱�A���26�g�έp���}�ƥ�]AE�^���o�ͤ�ҡA�b UPA 15 �@�J�B�C��g�֤U�`�gADA 40 mg�P�w�����դ��O��64.2%�B60.2% �P 53.2%�A�e��յo�ͪ���Ҭ۷��CUPA����礤�X�{�����}�����H�P�V�]�p�G�a��疱�l)�B�ٻĿE�ï��]creatine phosphokinase, CPK�^�W�ɡB�R�ߦ����]venous thromboembolic event, VTE�^���D�C�ӥt�@�ӿ�ܩ�JAK-1��� filgotinib �]�b�ĤT���{�ɸ��礤�����v���������צ��~RA�f�H�a����۪��{�ɧﵽ�A�é�2019�~12��16�鴣�X�s�ĥӽСC Upadacitinib�T���]�f�A�Ī��^JAK���MOA IL4+IL4Ra+IL13Ra1 ���ͫ�II�ƦX����A�A�ӴN����JAK1/2,IgE�U�媺�������l�C IL13+IL13Ra1+IL4Ra���ͫ�II�ƦX����A�A�ӴN����JAK1/2,IgE�U�媺�������l�C �H�W2�ӳ~�|���O�ѤW�媺IL4�BIL13�}�l�C ����JAK���������ġA�u��ϱ�Dupilumab �ʦ�IL4Ra ���T���ǻ������|�}�C ��ASLAN004���ĥi����f�A�Ī��A����IL4��IL13�T���ǻ���j�C �@�@���y�p�P��35�������]�P���窺�f�A�Ī��^ IGA0,1 15mg 48.1% vs 8.4%�]�t��40%�^ IGA0,1 EASI75=81% �A�[9-16�g�B�C�g�@�w�B�D�n�v����uEASI>41 ���ڸs�D �D��统AD�w�̥����Q�ư��D ............ EASI75 �h6/6���Ī�100% �t�~3�H���_�B���]��֬�2�H�B �ؼ�EASI75=81% ......16 �g�v�� �u�������|�B�p���q�Ҩ�����f�A�Į� �U�Ħy�p�P��@2==004 �����G1�ALebrikizumab ���AD�T���{�����ĥD�n����IGA0,1 ������Ӳա]16�g�^����y�p�P��45������(������R�v������R) 2�ADupilumab ���AD3���㦩����ӲաA��AD�y�p�P��80������(���q������l40���y�߾P��x55%=80��������AD.) 3�AASLAN004 2b �{��16�gx�C�g�@�w80%�u��Dupilumab�]������Ӳա^ ASLAN004 2b 16�gx�C�g�@�w�A���ij���f�A�ĤG�u �X�p��ASLAN004 �y�p�P�� 73�Q17��90������ IGA0,1 15mg 48.1% vs 8.4%�]�t��40%�^ ........ �ҥH���~�����G�u�Ѫ���Q2���Ѫ��Ӫ��n�D ���j�B2018/2019��Ӥ�O�K������2027�~.�ѩR�j �U�C2�ʫH�A������S���N�q�� ���� ���� ���ӤT���@�u���|�[�J�C�g�@�w�D �Y�p预��80%�u��Dupilumab �h�@�u�Ī��y�ݾP��73�������N�ܦX�z. 预��ASLAN004��3���{�ɨC�g�@�w���� �ҥH���q����G�u�{�ɬO�諸�D �@�u16�gx�C�g�@�w75�H�i�H���ΰ��D �b�\�h�A���g�W�b�a��SC(�֤U�`�g) �C�g�@�w�����X�B�A���C�G�g�@�w(���ĬۦP) �w�̤j���٬O���n�C�g�@�w�D EASI75 �h6/6���Ī�100% �t�~3�H���_�B���]��֬�2�H�B �ؼ�EASI75=81% ......16 �g�v�� �u�������|�B�p���q�Ҩ�����f�A�ĮġD �ЦU��j�j�g�H�� ASLN ���q �n�D�W�@��75�H���@�ux�C�g�@�w��AD �{�ɡD �������ij���f�A�Ī� AD �y�p�P��W��70������ �[��L�A���g>100�������� ���Ĥj��@��! (�b�w���P�������p�U) �ץ��@lDupilumab �s���3300����/600mg�B���q�X�t��x80%=2660����/600mg���禬 �s�y����=2660*10%=266/600mg 0.45 ����/mg ���]ASLAN004 16�gx�C�g�@�w���@�u�� 52%/28%=186% ���]�C��q���ۦP3300����/4�w ASLAN004�@ �u�Ī��i�P80�������i�� ����400mg*4=1600mg...ASLAN004 �����h�X1000*0.45=450����/�C�� 1800/24000(�~�����ĶO)=7.5%(17-52�g�i��_�ΤG�g�@�w/�|�g�@�w�D 80��x(60%-7.5%)=52�������b�Q ���סG��ij ASLN004 �C�g�@�wx16�g���@�u�Ī��i�Ϧy�p销���26�����G�g�@�w�B���ɨ�73������ �G�u�ıN�D�`�֡D(�]ASLAN004. �O�@�u�D�O) �GASLN ���q���N75�H���G�Ī��Ƚw�B �T���W�[�C�g�@�w���{��(�Pdupilumab) Dupilumab �s���3300����/600mg�B���q�X�t��x80%=2660����/600mg���禬�s�y����=2660*10%=266/600mg 0.45 ����/mg ���]ASLAN004 16�gx�C�g�@�w���@�u�� 52%/28%=186% ���]�C��q���ۦP3300����/4�w ASLAN004�@ �u�Ī��i�P80�������i�� ����400mg*4=1600mg...ASLAN004 �����h�X1000*0.45=450����/�C�� 1800/24000(�~�����ĶO)=7.5% 80��x(40%-7.5%)=26�������b�Q ���סG��ij ASLN004 �C�g�@�wx16�g���@�u�Ī��i�Ϧy�p销���26�����G�g�@�w�B���ɨ�73������ �G�u�ıN�D�`�֡D �GASLN ���q���N75�H���G�Ī��Ƚw�B �T���W�[�C�g�@�w���{��(�Pdupilumab) 1�ALebrikizumab ���AD�T���{�����ĥD�n����IGA0,1 ������Ӳա]16�g�^����y�p�P��45������ 2�ADupilumab ���AD3���㦩����ӲաA��AD�y�p�P��80������ 3�AASLAN004 2b �{��16�g�G�g�@�w���q��8%�u��Dupilumab�]������Ӳա^ ASLAN004 2b 16�gx�C�g�@�w�A���ij���f�A�ĤG�u �X�p��ASLAN004 �y�p�P�� 26�Q17��43������ IGA0,1 15mg 48.1% vs 8.4%�]�t��40%�^ �ڤ]�O���ݩ_�ݰ� �u�O�ثe�N�O���n���a����A��ۤ��� �o�ˤ��|�v�T�ۤv�߱� �γ\���Ѭ�M���\�F�N���o�@����] �]�������Ѳ��u�O�@�ӯ��_���ӫ~! ���ɬݦn! �^�ɬ��a! 1�~�e�A6�����ɭԻ��dzƼQ�F�աA�Ѫ��@�w���\�C 1�~��A0.35�����ɭԻ����q�@�w�����ݨ�ƾڡA�Ѫ��j���v���ѡC ���A�Ѫ����G�å��X�ӡA�ӭt�����C 6���g�R�A0.35�g��A���ܪ��O�H��-�l�����C�C��~~~~~~~~~~~�Q��9�I51���R�i70�U�ѡA�ѻ�0.365�������A��26�U�����A�x��830�U ���3�I40���R�i148�U�ѡA�ѻ�0.3405�������A��50�U�����A�x��1600�U �o�ⵧ���O�浧�w���w�ɥ���A�n�R���H�n����a(�n�檺�H�n���R�a)�A�����n����ɶ��M����A �{�b�O�ѻ�����C�I�A�ҥH�����ӬO���H�Q��C�ӬO���H�Q�R�C(��) ���]���i��O����浹�k��C �Ȥj, ���q�����զp�����]���Ĥ�סB�L�̬O���ƾڦb�⪺�M�a�B�ڥu�O�����պ�Ӥw�B ���L�ݤFASLAN004���X16�gx�C�g�@�w���{�ɳ]�p�N�o�̤��q�����Ӽ����D A+B=26+17 =43���������̰��P��2023�Q�~�����ʥ��Ȧ���20-25������ �C��20-25��������ȡD ------------------------------ �L�H�����ӬO�ѩR�S���L�̧C���@�� ���H�۩�嘞 9�I51���R�i70�U�ѡA�ѻ�0.37�������A��26�U�����A�x��830�U ���R�i�ȷ�d �ʤ�1�ѥ� �� ����w���~�����������ƾڡA�H�{�����ѻ��ӬݡA�ثe�����ƾڥi���٤W���F�i��;�ѷ�ͭn�h�I�@�ߤF�A���M�p�P�Ӱ��j�һ��o�@�ˡA���z��������A���٬O���ݦ��_�ݡA�ܩ�s��ʹN�ۦ�P�_�F�A�]�o��C���A���I�ۭt~�G缐75�HAD�{�ɸѪ����q��b2023�~�A���`�b�~���C�ҥH295�H�AQ2�Ѫ����i�A���|���G缐�v����ơC ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c11������q�̷s²���I �ӤH�� �@�B _________________________ ASLAN004 2B 16�g����� (�C�G�g�@�w) 295�H ��u��(EASI26~28) EASI75 69% VS 24% ASLAN004 ��T����u EASI�|����EASI31,��Ӳ����ķ|�U��. EASI75=15%//IGA 8~10% ���� : �p���q9/15�Ҽ���,�@�u������(�C�G�g�@�w) �i8% ��Dupilumab �w�b�����|�j. �G�BASLAN004 2B 16�g����� (�C�g�@�w) 75�H EASI75 73%~80% VS 24% ASLAN004 ��T����u EASI�|����EASI31,��Ӳ����ķ|�U��. EASI75=15%//IGA 8~10% ���� : �p���q9/15�Ҽ���,�G�u������(�C�g�@�w) �i��f�AUpadacitinib ���|�j. �T�B�����w�� �@�u�Ī�47%�۹��Dupilumab���n, �G�u�Ī� A+B=26+17 =43���������̰��P�� 1. ��u EASI29(15mg)//EASI30(30mg)//EASI28(��Ӳ�) ��u IGA=4 46%(15mg)//47%(30mg)//45%(��Ӳ�) clinicaltrials.gov/ct2/show/results/NCT03569293?term=NCT03569293&draw=2&rank=1 2.16�g ���� (1).EASI75 15mg 69.6% vs 16.3% (2).IGA0,1 15mg 48.1% vs 8.4% _________________________ EASI75 73%~80% VS 24% ASLAN004 ��T����u EASI�|����EASI31,��Ӳ����ķ|�U��. EASI75=15%//IGA 8~10% ���� : �p���q9/15�Ҽ���,�G�u������(�C�g�@�w) �i��f�AUpadacitinib ���|�j. ----------------------- A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up) --------------------------------------------------------------------------------------- RINVOQ® (upadacitinib) FDA ������ ĵ�i�G�Y���P�V�B���`�v�B �c�ʸ~�F�A�D�n���}�ߦ�� �������㪺�®�ĵ�i�A�аѾ\���㪺�B��H���C WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR See full prescribing information for complete boxed warning. �S���ʥ֪� Table 13: Efficacy Results of Monotherapy Trials at Week 16 in Patients with Moderate to 1.IGA0,1 Trial AD-2 Trial AD-3( RINVOQ+TCS VS TCS) 2.EASI75 Trial AD-2 Trial AD-3( RINVOQ+TCS VS TCS) �f�A���ĬO����,�i���Ƨ@�Τӭ�. Trial AD-3 �� RINVOQ+TCS ,�įq���j. 9/15 R&D DAYir.aslanpharma.com/static-files/d1f92c02-b2af-4f7c-8006-8c9cdcce4c5f P.38 2B 75�H ,�i����c: TREK-AD QW(�C�g�@�w) 47%---�G�u�Ī� Rinvoq (upadacitinib) ����5600����/��, ����Dupilumab 3300����/�� ��5600/3300=1.7�� ASLAN004 �G�u, �C�g�@�w*16�g���{�O�ΩMRinvoq (upadacitinib)����Ħ����i���۷����v���O. www.goodrx.com/rinvoq aslanpharma.com/app/uploads/2021/05/LB793-Poster_v2-SB2.pdf1A ���d�H���@�w SC(�֤U�`�g) 300mg/600mg �է�������u��7��. ��14�Ѧ�30%/10%���ϼu ���d�H���@�w IV(�R�ߪ`�g) 10mg/KG(60����600mg) �է�������30�� ASLAN004 SC�ͦ��v(���b���� �i�J�R���Ķq��v)�i�ण��50%. 1A ���o�d�H���@�w SC 300mg/600mg �է�������u��7��. ��14�Ѧ�30%/10%���ϼu 1b SC 400mg/600mg �����w��,�̾�TRAC/IgE �ͪ����Хi�O4~6�g����,�B�q�ĤT�g�}�l�N�F�۹�C�I. 2b SC 300mg/400mg Q2w/0/1/2�g�U���@�w��q��4�g�_�C�G�g�@�w���14�g.�ͪ����к����b���ɦ����|,��4�g��n�A���i�ण�|�Ӧh. �G���ĥi��M8�g/1-�w��1b�۪�. ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c clinicaltrials.gov/ct2/show/NCT05158023 295�H ���ĴN�j������ 1bmITT EASI75 69% VS24% (��Ӳ�)---�t��55% �]��2B �w��9�w ��1B 8�w. �������۷�. �ˬO�G�u��16�g16�w, �~�����| EASI75 73%//IGA0,1 57%. �h7�w��������. 9/15 R&D DAYir.aslanpharma.com/static-files/d1f92c02-b2af-4f7c-8006-8c9cdcce4c5f P.38 2B 75�H ,�i����c: TREK-AD QW(�C�g�@�w) 47%---�G�u�Ī� 47%*65%(dupilumab ���_�v)=30.55%------�G�u�Ī� �����멳�Ѫ��i�W�[�G�u�Ī�30.55% ��2023/3��16~26��, �p��ԹL1����?�_�h�n���~ �|���|3�����Ѫ���,����p�Ұ������7*80%*88%=4.92����/��,6�뤽�G�ƾڥ]�P7*80%=5.6����/�� ---------------------- 2021/3��1��줽�G�����Ѫ� 2021/3��4���]�P4����/�� 9/15�s�D�` ASLAN Pharmaceuticals �Ұ��{�ɭp���H��s Eblasakimab �b Dupilumab �g�����S���ʥ֪��w�̤����@�� ASLAN �p���� 2022 �~�ĥ|�u�}�l TREK-DX�]EblasaKimab �b Dupilumab eXperienced AD �w�̤�������^�A�H���� eblasakimab �@�����N�ͪ��s����w����ϥ� dupilumab �v�����S���ʥ֪� (AD) �w�̪����ĩM�w���� TREK-DX �N��s eblasakimab �b�����L dupilumab �v�����w�̤�����b�γ~�A�H�ɥR���b�i�檺 TREK-AD ����b�ͪ��ѯu���w�̤��i�� ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients ��In contrast to our Phase 2b trial in biologic naïve patients, TREK-DX will allow us to evaluate eblasakimab��s unique mechanism of action in a new patient population,�� said Dr Carl Firth, CEO, ASLAN Pharmaceuticals. ��We believe that many patients previously treated with dupilumab can benefit from eblasakimab, and this data could support the use of eblasakimab in both the biologic naïve and experienced patient populations.�� The TREK-DX trial is expected to enroll 75 patients in a randomized, double-blind, placebo-controlled, multicenter trial in North America to evaluate the efficacy and safety of eblasakimab in patients with moderate-to-severe AD previously treated with dupilumab. The trial will enroll patients who have discontinued dupilumab treatment for any reason, including inadequate control of AD, loss of access or an adverse event. The program is part of the Company��s existing operating plan and has no impact on its previously-reported cash runway. The trial will consist of a 16-week treatment period and a 12-week safety follow-up period. The primary efficacy endpoint is percentage change in Eczema Area Severity Index (EASI) score from baseline to week 16. Key secondary efficacy endpoints include the proportion of patients achieving Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear), proportion of patients with a 75% or greater reduction in EASI (EASI-75), proportion of patients achieving EASI-50 and EASI-90, and changes in peak pruritus. ��Dupilumab has played an important role in demonstrating the benefits of targeting the IL4/IL-13 signaling pathway in AD. However, some patients do not demonstrate an optimal or sustained response to dupilumab, or develop adverse events such as conjunctivitis, and thus seek an alternative treatment option that could offer an improved safety and efficacy profile,�� said Dr Alex Kaoukhov, CMO, ASLAN Pharmaceuticals. ��As we have seen in other indications, such as psoriasis, targeting different molecular components of the same signaling pathway can lead to different clinical outcomes and we believe that eblasakimab��s unique approach to blocking the Type 2 receptor may offer an effective treatment for dupilumab-experienced patients.�� ASLAN is also conducting the TREK-AD trial, a global randomized, double-blind, placebo-controlled, dose-ranging, Phase 2b clinical trial, to evaluate the efficacy and safety of eblasakimab in adult patients with moderate-to-severe AD who are candidates for systemic therapy. Topline data from this trial is expected in the first half of 2023. ASLAN��s management is hosting a Research and Development (R&D) Day on Thursday, September 15, 2022, from 10:00am to 1:30pm ET at the St. Regis Hotel in New York. To attend the event in person or virtually, please click here for registration. A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN Pharmaceutical��s website at ir.aslanpharma.com/ 1.H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Aslan Pharmaceuticals (ASLN �V Research Report) today and set a price target of $7.00. The company��s shares closed last Friday at $0.40. H.C. Wainwright Sticks to Their Buy Rating for Aslan Pharmaceuticals (ASLN) Oct 31, 2022, 06:15 PM www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-aslan-pharmaceuticals-asln?mod=mw_quote_news 2. Aslan is conducting the Phase IIb TREK-AD study of eblasakimab in ~300 moderate-to-severe atopic dermatitis with top-line data expected in 2Q23, and the company ended Q3 with cash of $69M, Tenthoff tells investors in a research note. Aslan is also planning a Phase II study of DHODH inhibitor farudodsta in skin autoimmune disease that will commence in 1H23, the analyst adds. Read more at: �p�G����~3��26��e�A004 2b����ƾڦn�a�A��z�έp��ƮɡA���Ӧ��N�߲z���� �Y�ѻ�������s�W1�����A�N���j�ѪF�Ϊk�H�w���{�P�Ӥ��q�A���@�A�W��C �ڻ{���ѷ�_���^�ͪ����|�w�L�G��L�A���ɥu����{�� �ۤv�����q�ۤw���Ͻַ|�ϡA�j�a�u������ �Ъ`�N�A���~3��26��e�Y�ѻ����s�W1�����C �B�n����W���C ASLN ���q��k �ثe���q�A2b���Ѫ�资�Ƥ��G������b2023�~�ĤG�u�C ... ���b�ĤT�u�סA�ڭ̴Neblasakimab�b���g����o�M���g�q���������P�@�ξ���X�F�\�h�s�����n���ѡA�H�λP��o�M�ίv�ॢ������ AD �w�̪���b�ﵽ�A�o�q�`�O�o�DZw�̡A�� ASLAN Pharmaceuticals ���u����x Carl Firth �դh���ɹD�C���ڭ̴��� 2b ���ƾڦb 2023 �~�� 2 �u�צb�ͪ��ѯu���צܭ��� AD �w�̤�����eblasakimab���D�n�ƾڡC�b�ڭ̱N�q TREK-AD �M TREK-DX �ͦ����s�ƾڤ��e�A�ڭ̥��b�q���b�i�檺��s�X�@���إߤ@�M�j���O�����ѡA�o�ǦX�@�N����~��i�ܡA�H���eblasakimab�㦳�@�������� AD ���t���ƪv������O�A�b 2 ���X�ʪ����g�ʯe�f���㦳�s�x���v����O�C�� 2022 �~�ĤT�u�פΪ���~�ȫG�I �̥��Ի���� 8 ��A���q�P Belle.ai ñ�p�F�@���\�i��ij�A�Ω�b���y�h�ӯ��I�ϥ� belleStudy ™�Ʀr�Ϲ�����n��A�Ω� AD �����b�i�檺eblasakimab�� TREK-AD ��s�C����ϥΪ��ѨM��ץi�H�q�L�Ϲ�����зǤưO�� AD �e�f�Y���{�����A�ӧN�N�� ASLAN ����i�@�B�[�j��b TREK-AD ��s������q���s�{�ǡC �ֽ��ۨ��K�̩ʯe�f���{�ɶ}�o�p�����b�̫�V�w�A�w�p 2023 �~�W�b�~�}�l�i�� 2 ������C �� 2022 �~���A�Ĥ@��w�̰ѥ[�F TREK-DX ����C finance.yahoo.com/news/aslan-pharmaceuticals-reports-third-quarter-110000300.html �� 2022 �~ 9 �� 30 ��A���q�H 6,890 �U�������{���B�{���������M�u�����������d���g�窬�p�F �w�p�� 2023 �~�����]�D ��s eblasakimab �b dupilumab ������O���s TREK-DX �{�ɭp���g���F�S���ʥ֪� (AD) �w�̡A����b 2022 �~���e�۶ҲĤ@��w�� eblasakimab �b���g�ͪ��v���L�����צܭ��� AD �w�̤��� 2b �� TREK-AD ���祿�b�i�椤�A�w�p�N�b 2023 �~�ĤG�u�ײ��ͤ@�u�ƾڡC Company maintains healthy operating position with US$68.9 million in cash, cash equivalents and short-term investments as of September 30, 2022; expected runway through late 2023 New TREK-DX clinical program studying eblasakimab��s potential in dupilumab experienced atopic dermatitis (AD) patients on track to enroll first patient by the end of 2022 The Phase 2b TREK-AD trial for eblasakimab in biologic naïve moderate-to-severe AD patients is on track and anticipated to generate topline data in Q2 2023 ���j�A�]�G���N�A 11�뤤���A����Q3�]���A���p�|�ť�2b ���ק����C �����~2�뤤��-3��W���Ѫ��C �ѩR�j�p��2���}���}�e�C�A�S�X�j�q�A�۩��i��ܡA �Q�F�ѱz���ݪk ���v�̧C��0.3555�֨�F�q�`���ѹL�����q�A�������o�_�� �����o�_�Ӫ����q�A�q�`�n�B��F �[�o�I�ȷ��ܶ���I�ѻ��w�g�z�ը칳�Q���@�� �ڤw�g�����ݸѪ�������i��F �N��۷��ֳz�A�[�[�Ӫ��W�ݤ@�U���j�A ���] ��� Lebrikizumab 2b ���� clinicaltrials.gov/ct2/show/results/NCT03443024 1.IGA0,1 4�g�@�w 125mg =22.6% p=0.1917(p��>0�P05�^ 2�PEASI75 4�g�@�w 125mg =43.3% p=0.0610(p��>0�P05�^ 280�H�@4�աA58�Ӥ��ߡA����4.82�H������ �H�W�]�p�A�Y�Ϧ��C�ӤH���C�G�g��ơA�p�G�L�Ѫ��A�ݤ��X�C�ժ����ġC ASLAN004 2b �A��h�զ@5�աA���]295�H��65���ߡ�4�P5�H/����⋯⋯ �Ѫ���ા�x�A�U��p�ȡC ir.aslanpharma.com/static-files/60a95013-835e-4341-9b3b-270ce73b9b1d2022/Q2 ASLN �]���A�p�W �b��3200�U���� ��2022/Q4. �b�Ȧ���600�U���� finance.yahoo.com/quote/ASLN/?p=ASLN ASLN ���L����3080�U�����C ASLN���q�ѻ��A�ثe�H�]�P��Ӫ����ȳ̷ǽT�C 2b �Ѫ��ƾڡA�Y�p�w���]�p 1bmITT EASI 69%/IGA 44%),�ؼл�7�����A�U���]�P��5�D6�������ѡC �`ı�o�ثe�ѷ�ѻ��A�����O�Ѫ������G�n�W�V��������Lebrikizumab���˺A�A�Y�ϸѪ����W5���A�]�u��2.25�A�u�O�����Ӥw�A���I�OCEO�n�V�O�@�I�A�h�����ѻ��A���M������c�Ӹg��]�����C���j�A�H�U�ӤH�[��C ����p���s�ĪѪ��ѻ������ȱ`�b�����ĵ��ɱ���Ѳ��b�ȡC ���o�ĵ���3�Ӥ몺���Ȭ�����C�����{�i�y�p�P���Bx3���C �Q���ʻ���=�C�~��~�b�Ȫ���{�� �]�pLebrikizumab 2019�~�������ڬw�ϾP��A�W����5�~�̰��P��15�������A�C��~�Q�q��{11�������^�A�̫�11�������Q���ʡC ���ʤ��q�i�b�b�Ȫ���¦�W��T���H�W�ѻ����S�C ���q�D�ޥD�n���J�A�Ҿa�Ѳ������A���ꤽ�q���ѧQ�ҵ|���A�ҥH�h������ҶR���q�w�êѡC CNTB���qCBP201 AD 2b �Ѫ���(�q2021/07/28)�A�ѻ��b����23-28�����A11��19�餽���Ѫ��ƾڡA�����4�����h�C DERM���q Lebrikizumab AD 2b �Ѫ�/����(2019/02/07)�����C �ѻ��b�C��6���h�����A�Ѫ�����j��约�@����12�������k�C 2019�~10��}�l�T��AD�{�ɡA�ѻ��^�쩳�I6�������k�C 2019�~12�� 18�����h/�ѡA�Q§�Ӥ��q�ť����ʡC �P�±z���^�_ �i��O�x�Ѥ��u������Y�� �ѻ����շ|���ϬM���q���ӡA�]�����H�w�����D �Ҧ��{��004 2b�ƾڥi�ण�� �z�������a���q�ѻ��̧C��6.6�� www.clinicaltrials.gov/ct2/show/NCT04444752?term=NCT04444752&draw=2&rank=1 CBP 201 AD, 2b �L���ѻ��A���s�ʲ{�H�C finance.yahoo.com/quote/CNTB/ 2021/08/10 �̰��ԤW28�����C (2021/7/28 �i��w�Ѫ��H�H�H) ��Ĺ�b�Ѫ��餧��C 004 2b�����q8��26���A �Y�L����i�ק�s��� DERM (Lebrikizumab ) 2019/02/07 AD2b �Ѫ� DERM �ѻ����աA�p�U www.netcials.com/stock-price-chart-history-nasdaq/DERM-Dermira-Inc/ �ѩR�j�̪���Q�� ����ѻ������C ASLAN004 1b mITT�]8�g�v���^ vs 2b ITT����� �]16�g�v���^//��Ӳմ���ȡ]16�g�^//(������Ӳի�Pk�^ EASI75 =69% vs 73%// ��Ӳ�24%//(�t�� 45% vs 49%)---�ץ�-1(���_�v3/16,�i��U�ר�1/16.��ɥi��A�Ԥ�EAS75 ��80%�H�W���v���p) IGA0�A1 =44% vs 57%//��Ӳ�15%//�]�t�� 29% vs 42%) �@�@�@�@�@�g16�g�v����IGA0,1 �|�A�����A�pLebrikizumab 2b/ph3 EASI75 �MIGA0,1�t�Z16%�]16�g�^ Lebrikizumab 2b//ph3 �P�˼v�TIL13a1,���ħѦһ��ȡA�u�OASLAN004 �IJv��֡C �Y�����ѻ���18.5�����H�W�A���p�����Ҩ�3���{��4������������C �ݦA�l�}�ѪF�|�X�W�ꥻ�B�C���p�ܤּW�[��50%�A�W�[��ADR150�A000�d�� 75�A000�d��x7��x80%x97%=��4�������]����DERM AD2b�Ѫ��᪺����s�q�^ �t�@�覡�N�O���ѻ���18.4�����H�W 18.4x80%X97%=14.28���� 4������/14.28=28,000�d��ADR�]���ΦA�X�R�ѥ��^ ���ȩԤɦ�15~18.5�������H�W�A�p���Q���ʻ��A�@��40��������n�͡C ���q�n�[�o��ILebrikizumab AD �̰��P��w�O�u����45�������C ���q���X��1b�����Z��ƨ��H�������v�e����ưѦҡG aslanpharma.com/news/?cat=publications �p���v�ͧP�A�N�̾ڸѪ��ƾڨөw���ȡC ���Ѫ��A�L�ջ��ȡC ƿ�@�@�@�@ ASLAN004 EASI75 =69% vs 73%// ��Ӳ�24%//(�t�� 45% vs 59%) IGA0�A1 =44% vs 57%//��Ӳ�15%//�]�t�� 29% vs 42%) �@�@�@�@�@�g16�g�v����IGA0,1 �|�A�����A�pLebrikizumab 2b/ph3 EASI75 �MIGA0,1�t�Z16%�]16�g�^ Lebrikizumab 2b//ph3 �P�˼v�TIL13a1,���ħѦһ��ȡA�u�OASLAN004 �IJv��֡C �̾�DERM ���qLebrikizumab AD 2b,2019/02/07�Ѫ�,02/12�ڬw�ϰӷ~���v�O���v. ASLAN004 2022�~10��15��ASLAN004 2��, �w�����̫�@�H�B���Ĥ@�w. �{�b���q���Ӧb�����? 1.Lebrikizumab 2b ����PK(��uEASI25.5) EASI75 61% vs 24%(�t��37%) 2.Lebrikizumab ph3 16�g ����PK(��uEASI???) EASI75 59% vs 16%(�t��43%)�K�K�K�K�l�[��52�g����组����47% (2)AD2 EASI75 51% vs 18%(�t��33%)�K�K�K�K�l�[��52�g����组����41% (3)Lebrikizumab�QTCS 3.ASLAN004 2b ����� 4.Dupilumab ph3 16�g (3)Dupilumab +TCS A.EASI75 16�g63.9//68.9//23.2 B.IGA0,1 16�g39.2//38.7//14.2 5�BLebrikizumab �y�p�P��预����������v45-150�������C �H�U�P�ݭӤH����A ASLAN004 2b �{�� ���]65�Ӥ��ߦb2022/08/30�}�S���̫� ⋯⋯⋯�̾�Lebrikizumab 2b�{�ɪ��ɵ{�g��C ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ Lebrikizumab 2b �{�ɰO�� 2018/8/23 �̫�۶Ҥ���资�Ƨ�s ���ק������ݨ̾�Lebrikizumab 2b�{�ɱ����A ���]8��30��65�Ӥ��߬��̫�פ��߶}�]�A�g45�Ѫ��z�˩Ұ���]�PLebrikizumab) �@���̤��q�������ǡC �ѩR�jASLAN004 2b�w�����̫�@�즬�סA�O�_���@���״X�H����T�� �̾�Lebrikizumab 2b ���{�g��C�� ASLAN004 2b AAD 2023 �̷s��s�פ�`�� �̫���G2023/01/13 �аݦU��j�j:���Y004��112�~2�뤤�Ѫ����V�A�аݨӱo�ΰѥ[���~����ֽ��Ƿ|(�q���)��? (��(111)�~����ֽ��Ƿ|�O�b3��25���|��). §�Ӥ��q�b9��8��o�� Lebrikizumb �T��52�g�{�ɳ��i ���q�۫H ���ڭ̦b�S���ʥ֪��{�ɸ��綵�ؤ���o��í���B�㦳�{�ɷN�q�����G�A�ڭ̬۫H�A�p�G��o���Alebrikizumab �i�ন���ֽ�����ͤΨ�\�h�w���ϤH�I�z�g�������צܭ��ׯe�f�w�̪��@�u�v���Ī��ôM�D�s���v����ܡA�ç���w�������W�c�����ġA��§�Ӥ��q���y�K�̾Ƕ}�o�M��ǨưȰ��`�� Lotus Mallbris ��dzդh�� finance.yahoo.com/news/lebrikizumab-dosed-every-four-weeks-121500944.html �̾�Lebrikizumab AD���O�u�P�����45�������C004 2b �Ѫ��p预�� IGA0,1 57% vs Leb. 2b 45% vs ���组15% ���] ��uEASI 26-EASI 28 �h��bAD �QASLAN004 ���ʪ��B 约��2020�~Leb.�Q�֪��B 11������x3��=33�������_���C(���ɦ�15���������y�p�P��K�K����欧�w区) ��L�A���g=33/0.55-33=27������(2������) 33+13.5=46.5������ ���p�Q���ʻ��b45-50�����������C ���]1000,000�d��ADR �ѥ� �C��45-50���������C �W�L�]���N�~�C �H�W�ӤH����C ASLAN004 �����u��Lebrikizumab ,�]MOA���Y�A���ĵL�kí�w�A�ɦn���a�CLebrikizumab �x�b���ݡ�COPD �T���{�ɥ��ѡA�x�����{�ɸ���C Lebrikizumab �ȦbAD���P��N�Q����45�X150���������y�p�P��C 1�ALebrikizumab �T���{�� AD1. AD2 2�ADupilumab �T�� IGA 53% vs 15%(�t��38%�^ Lebrikizumab �y�p�P��45�������@�@�@������R�vEdmund Ingham�� �̰��w����150�������C 2022/09/28 �峹�p�U I am more optimistic on sales of 2 newcomers however in Lebrikizumab and Mirikizumab. Lebrikizumab has been compared to Sanofi��s Dupixent, itself forecast to achieve peak sales of ~$15bn by some optimistic analysts, and has even outperformed Dupixent in some studies, so perhaps I am being too conservative forecasting peak sales of just $4.5bn. Lebrikizumab �M Mirikizumab �� 2 �W�s�Ī��P����[�C Lebrikizumab �P�ɿյ᪺ Dupixent �i��F����A�@�Ǽ��[�����R�v�w�p��P���B�p�ȱN�F��� 150 �������A�b�@�Ǭ�s���ƦܶW�L�F Dupixent�A�ҥH�]�\�ڹL��O�u�a�w���p�ȾP���B�Ȭ� 45 �������C Eli Lilly: Valuation Feels Impossibly High - Don��t Board This Hype Train Sep. 28, 2022 12:26 PM ETEli Lilly and Company (LLY)9 Comments Edmund Ingham seekingalpha.com/article/4543610-eli-lilly-valuation-feels-high-dont-board-the-hype-train ����ӽдX�~��W�����i��A ����2�� �D�n����IGA 0,1 ��30.3%���C. �Q��CNTB�ѻ��S�C��1�����A��0.95�����A���b�̭p���b���ꥫ���Ҷ�3���������T��AD�{�ɡC CNTB 2023/10/04 ���G CBP201 ����2 �����@����AD�{�ɸѪ����i �@�@�@ CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe AD Safety and tolerability results for CBP-201 consistent with targeting the IL-4R�\ pathway Data support advancing the regulatory discussions with the CDE for submitting an NDA in China ����� vs. ��Ӳ� The primary endpoint of IGA of 0 or 1 (��clear�� or ��almost clear��) with at least 2 grades of reduction at Week 16 from baseline was significantly greater for the CBP-201 (300 mg every two weeks) group with 30.3% of patients showing improvement compared to 7.5% for the placebo group (p < 0.001). CBP-201 also met key secondary endpoints, including 83.1%, 62.9% and 35.8% of patients achieving a 50%, 75%, 90% reduction in the Eczema Area and Severity Index score (EASI-50, EASI-75, EASI-90) from baseline compared to 41.1%, 23.4% and 6.3% for the placebo group (p < 0.001), respectively. Significant improvement in pruritus with 35.0% of patients experiencing a reduction of 4 or greater on the Peak Pruritus-Numerical Rating Scale (PP-NRS) compared to 9.6% for placebo (p < 0.001). A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China 10��7��̷s�����q²�� ASLAN004 2b �{�ɡA�w���Ѫ�����G2023/02/15 ⋯⋯⋯�̾�Lebrikizumab 2b�{�ɪ��ɵ{�g��C �p�����W���A���Ӥ��|���������i�C ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ Lebrikizumab 2b �{�ɰO�� 2018/8/23 �̫�۶Ҥ���资�Ƨ�s ���~�즳�H��z���峹 �̭�������ASLN004������ ASLAN004 is a fully humanized antibody directed against IL-13R�\1, thereby blocking the binding of IL-4 and IL-13 on the type II receptor (IL-4R�\/IL-13R�\1). Owing to the more selective binding compared with dupilumab, ASLAN004 may provide the option of a low-dose regimen and a better safety profile. An interim data analysis from a phase Ib study showed that the com- pound is well tolerated and provided promising efficacy data, with 67% of the patients achieving EASI75 versus 0% in the placebo groupclinicaltrials.gov/ct2/show/NCT03443024 Lebrikizumab 2b �{�ɰO�� 2018/8/23 �̫�۶Ҥ���资�Ƨ�s (65%��16-27%��2)/14=70%�P�P�P�P��断�v�վ㬰1�H�A1/14=7.1%�K �K�K�K��8�g���������ġC Pk Dupilumab ����8�g�q�� ��65% 70%/65%=108%�K�K�K�KASLAN004�b��8�g�������Ħ�8%�u��dupikumab���ͶաC 1�Bwww.nejm.org/doi/full/10.1056/nejmoa1610020 �ϤG�C 2.ASLAN004 1b mITT EADV(2022) �ĤG�Ӵ��Z 3.PK �U��EASI50 ASLAN004 �b�ĤT�g�F��ADupilumab �b�ĥ|�g�~��F�C 004 1b mITT TRAC/IgE ��20�g����ƦU�g�ͶչϡC �b���qEADV2022 ���Z�C TRAC���Цb��3�g�N�X�G����̧C�C IgE �b��12�g~14�g����̧C�C (��7�g�̫�@�w) �ͪ����Цb��8-11�g��维���b�C�ɡC ���q��2b�{�ɪ����w�]�p�ܤj�����Ӧۥ����i�C �ٰѦҡAPK�A�����A��Է�v���C ���N�ODupilumabASLN �u�����]赢8%�C �n�n��sDupilumab���ASLAN004 1b mITT. �K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K Dupilumab �U���{�ɼƾڡC 1. Dupilumab �����|�� AD �{�� 4�g/12�g , Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis www.nejm.org/doi/10.1056/NEJMoa1314768 2. Dupilumab 2a/2b �{�� ,2018/SEP journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx 3.Dupilumab AD 2�ӤT���{��, 300mg/�C�g�@�w/300mg/�C�G�g�@�w Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis 0,1,2 �U�@�w�A��21�Ѯɶ��A 200mg/400mg/600mg(��lb mITT),�������ĥi��EASI50, ���]�̫���������FEASI75 , 3�w�N�i�F66%����终���G�C(50%/75%) ��L���|�g�@�w�ݳy�ƤF�A�p�G�F�дN�h�Ƚu40%�����n�סC(�۹��dupilumab ,�i�F54%.) 2�g�@�w4/6/8/12/14�g�U���@针300mg/400mg, ������dupilumab,赢8%�_�h�u�७�������C �K�K�K�K�K�K�K�K�K�K�K�K�K�K �ɶ��O�ڭ̳̦n���B�͡I���j�A �ӤH�P�_�C �ثeDupilumab �ڬw�P�����12%�A �Y�n�}�ڬw��������9��N�n���i�C �H�W�ӤH�q������]�C �Ш̤��q���i���D�C �Y�u���u�}65�ӡA�A��11�뤤���U�����Ӥ��i�����̫�@�ӡC �ѩR�j���פ��߬O�_�Ȱ��d�b65�B ���A�s�W�A���Ѥ��q�����䥼�Ӿާ@���e�A 004 2b clients. ���ʤ��: �٬O���b8��30 ��. �ӤH�q65 �Ӥ��߬��̫᪺�۶Ҥ���. �O���C �аݤѩR�j�H�U��p�ɤ���h�z�Ҵ��o�O�P�@��ƶ� ? �Y�O�A�N�O�z�]�{�P�~���������ƾڡA�u�O���V�P�_��?�|���G�ѩR10141925 �o���ɶ�:2022/9/30 �W�� 09:52:19�� 5668 �g�^�� ���|���������i�C ���~3���Ѫ�295�H�����v���C �Y须100�Ӥ��ߩ۶ҡA�������R�N�i�ର���n�C �|���G�ѩR10141925 �o���ɶ�:2022/9/30 �W�� 11:22:32�� 5670 �g�^�� �]�O2023�~3���C �H�W�ӤH�q���C �رi�j�A�u�}65�Ӥ��ߡA12�������Ѫ�+�p�ҡA�O�۹�X�z�B�w������סC�ѻ��w�g���O���ȷ�d�U�������D�F�A�N��112�~3��27��ѻ��٧C��1�����A ���q�٬O��Q�δ�굥��L�覡(���q�b���i��������)���ȷ�d�@���d�b�����F�J�ꥻ�����C ���פ��ߥثe��65�B�A�O�_�A�W�[? ���]65�B���פ��߬O�̲��G 111�~11��6���q��W�w�g���@�b���v�H�����Ѫ��ƾڡA�p�һ��O�_�}�l�s�ʡK�K ���|���������i�C ���~3���Ѫ�295�H�����v���C �Y须100�Ӥ��ߩ۶ҡA�������R�N�i�ର���n�C �]�O2023�~3���C �H�W�ӤH�q���C 65*5=325 �D�`�������۶ҹw���H�ơA���ֻ{�u�J�Ӧ��סA�����������V�ƾڡA�������{�P�ѷ�g���V�C�[�o!�ѷ�clinicaltrials.gov/ct2/show/NCT03443024Lebrikizumab 2b AD �{�� 4组/280�H�C�}58�Ӧ��פ��ߡA���b����C 2019�~2���Ѫ��A7�ѫ�ñ�p欧区���v�X约�C ���B�[�}36��(30+6)�D�w6/�L��8/纽����1/�s�[�Y4,�p�p19�Ӥ��� �X�p65��004 2b�۶Ҥ��ߡC 欧�w�������۶Ҿ��v�D�`�j�C 004 ��2b �{�ɡA�w�}��65�Ӧ��פ��ߡC 8��30��ܤ��������ʡC 欧���M����FDA����ñ�p�{�ɹ���资�Ƥ��۩ӻ{���X约�C �ҥH�b������o�ĵ����{��资�i�������h�ӽ��ĵ��A�p���Ϊ��R���f�ĵ��C 8��30��}�ߤ����� 004/2b ��断�v EASI75:(11+5)/22=73%�K�K��lbmITT+���g�վ�预��5/6 IGA0,1=EASI75 73%-16% (��Lebrikizumab 2b 2�۫��Юt���Ҧ�) �G2b ����Ȧ� �H�W�i预������3���γQ���ʻ��Ȫ��ѦҡC Ph3 ����uEASI�|�Ԥɦ�32-33.���组���Ħ۵M���C�C Ph3.�����_�v�b����ճq�`��7%-8% �]��2b�Mph3(�T��)�A�������组���D�n�������� Lebrikizumab �]M0A����A�G�ӤT���{�ɮt��30%���ġC Dupilumab 2�ӤT���AIGA0,1�������组��P��28% ASLAN004 ���ӷ|�PDupilumab ,3��2���{�����ĸ��@�P�ʡC Lebrikizumab 2b vs ph31.EASI75 2b: 61% -24%=37% Ph3: 2.IGA0,1 ���y�P���v�b���oBTD�A �ΥH1/2���{��资�ƥӽ��ĵ��C �H20���������v给����詤���t�@�a���q�C �ѻ��q3-4����(2015�~��BTD) ��Ӥj�ѪF���P�N�A�}��CEO�A �ۦ�W资�A�����T���A2020�~����o��证�C 2020�~��200�������Q���ʡA�ѻ�90�������k�C Tang 资���z�w���o5555�d�ѡA��8%�A ���靈��O�v�T���q�M���C www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/#!po=33.4821Lebrikizumab 2b �{��资�Ʀp�W�C ���组 ��uEASI28.7 EASI75 24% �٬O�i�ޥΡC �]��004/2b ���ؼ����ġA维�����e Dupilumab 3��SOLO1/SOLO2�A�������组 Pk(�������组) ASLAN004 �u��Dupilumab 3��SOLO1/SOLO2 ���ͶաC �H���ּw����C �߬�Ǽƾگ�H���C CAPITAL MANAGEMENT �A����R�i�J�DASLN�A�O�i��C �ѻ���20�����A�N�u�u�j�Ȥ@�i�C ............�K�K�K�K�K�K�K�K�K�K ASLAN004 2b�ؼ����ĭץ��C(���组) ��u EASI (31.2��16+19��6)/22=27.9.�K�K1b/aslan004 ���� �K�K�K�K�K�K�K�K�K�K (24%-16%)/(31-25.5)=1.46 内���k EASI27.9=24%-2.4%��1.6=20% ASLAN004(��uEASI28) EASI 75 =73% vs 20%//�t�� 53% IGA0,1=57% vs 12%//�t�� 45% �ѷ�n�ǥx�W���İ�X���g���O�A�Ѫ������ٯ�N�ѻ����b60���H�W�A�N����ɶ��h���ߺ�������; �ݨ�TANG CAPITAL MANAGEMENT�ܦ�����,���Ѥ]��,�o�ʩ_ŧ�ӷ���ɶ��h�]�O����~�ѩ�Dupilumab +TCS �[TCS��Dupilumab,�bEASI75�W�[45%�����ġC �G须��SOLO1/SOL2 q2w �A 16�g���� ESSI75 47.5%����¦�C�K�K�K�K�K�KA IGA0,1 ����37%�K�K16�g IGA0,1 ����35%�K�K52�g(��Dupilumab+TCS 52/16�g��2.5%)�K�K�K�KB B/A=74%. �G60�g�jpK�Ҧ��G�A�p�U�C Dupilumab 74% vs Leb. 75% vs Tra. 1.IGA0,1 Dupilumab+TCS 52% vs Leb. 75% vs Tra. 50% 60�g维���v�C(�T��AD�{������)�jPK1.IGA0,1 Dupilumab+TCS 52% vs Leb. 75% vs Tra. 50% 2.EASI 75 60�g维���v Dupilumab+TCS 95% vs Leb. 80% vs Tra. 55% ���G �K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K�K QW//Q2W//��Ӳ�--% 16�g39.2//38.7//14.2 2.EASI75(%) QW//Q2W//��Ӳ�--% 16�g63.9//68.9//23.2 52�g/16�g=95%, �����h5%�A维���v95%. 3.IGA0,1 �����v ,Q2W, A/B=36/68.9=52% �G�BLebrikizumab 52 �g维���v�C Lebrikizumab 250 mg IGA (0,1) 74 %//76 % 2�PADvocate2�]�b��16�g51%�FEASI75�^ �T�BTralokinumab 52�g�����v (1)ECZTRA 1 (2)ECZTRA 2 ������ܯǴ��F�J�ꥻ�����W�����q�� Notice of Transfer of Listing to The Nasdaq Capital Market �ȴ����ķ~�������q Shawn Kwatra �դh�M Madan Kwatra �դh�X�@���Ĥ@��ƾ���ܡA�S���ʥ֪� (AD) �w�ֽ̥��˥����Τj�ӭM�M�ݻĩʲɲӭM�� IL-13R�\1 ���F�W�[�A�W�j�F IL-13R�\1 ���֤ߧ@�� Eblasakimab ��ۭ��C�F�Ѥ��P�� IL-4 �M IL-13 ��o�~�|�ް_�����g����o�ӷP�ʡA�åB�T�w�F IL-13R�\1 �H���b���� AD �H�~�����g�����ĩʩM�ӷP�ʤ����s���@�� �[�Q�֥��Ȧ{�������J�M�s�[�Y�A2022 �~ 9 �� 28 �� (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) �O�@�a�{�ɶ��q�B�H�K�̾Ǭ����I���ͪ��s�Ĥ��q�A�}�o�зs���k�H���ܱw�̪��ͬ��A���ѫť��F�b�� 51 ���ڬw�ֽ��f�Ǭ�s�Ƿ| (ESDR) �|ij�W���зs����Ʃʨ̥��Գ߳�ܼƾڡC 2022 �~ 9 �� 28 ��� 10 �� 1 ��b�������i���S���|�檺�j�|�����A��T�����H�q�l�������Φ��e�{�C ���b ESDR �W�i�ܪ��s��Ƽƾڬ� AD �� IL-13R�\1 ���ɪ��ӭM�]�l�H���Ǿɴ��ѤF�s�o�M�t���ƪ�����ѡC�ڭ̻P Shawn Kwatra �դh�M Madan Kwatra �դh�X�@����B�ƾ���ܡAIL-13R�\1 �b�Τj�ӭM�M�ݻĩʲɲӭM�������F�����A�o�O AD ���g�������X�ʦ]���A�b�o���ֽ����f�ܳ���A�[�j�F IL-13R�\1 �b���� AD �f�z�ǡA��ASLAN Pharmaceuticals ��Ƭ�ǭt�d�H Ferda Cevikbas �դh���C �����~�A��]���F���ܤƪ��� 1 ���M 2 �����餧���s�b���H���Ǿɮt���A�w��o�Ǩ��骺�Ī��i��㦳���P���U������A�q�ӾɭP���P���{�ɵ��G�C�Ӧۯ��g����s���ƾ��ҹ�F�ڭ̤��e���o�{�A�Y IL-13R�\1 �H���Ǿɹ�g���q�L�S�w��o�������o�~�|���ӷP�ʫܭ��n�A�í������� IL-13R�\1 �H���Ǿɥi��b���� AD �H�~�����g�����ĩʩM�ӷP�ʤ譱�o������@�ΡC�o�Ǽƾڤ���F IL-13R�\1 �@�� AD �v�I�����n�ʡA�� eblasakimab � AD �w�̪����g�M��o���ѤF�@�ؼ�b���t���Ƥ�k�C�� 2022 ESDR �q�l�����Ա� ���� 1 IL-13R�\1�H���b�S���ʥ֪������Ŷ��w��M�\��@�� �Q�� AD �O�@�غC�ʪ��g�ʥֽ��f�A���㪺��o�]��o�^1�C�o�OAD�w�̳��i�����c�����g���C IL-4/IL-13 ����t�άO�g�{�����Ҫ� AD �v���v�I�A�� 1 ���]IL-14R�\1 �M���@ �^ ��^�M 2 ���]�� IL-4R�\1 �M IL-13R�\1 �զ��^����զ�2 .�����i�ܤF�� AD �w�ֽ̥��� IL-13R�\1 ���F�Ҧ������R���G�A�ûP���d��Ӳնi��F����A�Ӭ�s���b�q�L�K�̲�´�ƾ� (IHC) �M�Ŷ��w���n�a�F�� IL-13R�\1 �b AD �����@�ΨϥΤ������վǨӴy�z 1 ���M 2 �����骺�\��C ���G �ƾ���ܡA�P�ǰt�����d��Ӭۤ�A�l�� (L) (P<0.001) �M�D�l�� (NL) (P=0.45) AD �ֽ��� IL-13R�\1 ���F��ۼW�[�C���~�A�P�ǰt����Ӭۤ�AL�]���O�� P = 0.034 �M P = 0.024�^�M NL�]���O�� P = 0.031 �M P = 0.046�^AD �ֽ����Τj�ӭM�M�ݻĩʲɲӭM�W�� IL-13R�\1 ���F��ۼW�[�C�Χܱ`�� �^ �������� 1 ������ɭP MMP9 �����F�W�[�]P<0.001�^�A�o�O�@�ؽ���酶�A�b AD �w�̤��ɰ��A�åi��[�@���g�P�i��´���~ 3�B4�C eblasakimab �� 2 �����骺����ɤF��]�A�G�����ɪ� 2 ���s���M�ӭM�]�l���ͩһݪ� XBP1�]P<0.001�^�M CXCL8�]P=0.046�^�b������]������A������P AD �Y���{����6�C ���� 2 ���� 2 �̥��Ԩ��ܹv�V�ղӭM���� 13 ���� �\ 1 (IL-13R�\1) �}��s����o�~�|�M�۵o���g������ �Q�� IL-4 �M IL-13 ����o�~�|�M���g�����ĩʦ����㪺�v�T�A�i�H�q�L�v�V IL-13R�\17,8 �ӧ���C Eblasakimab �H���˩M�O�P�H 2 ������Ȱ� IL-13R�\1 ���X�A���� IL-4 �M IL-13 �q�L�b�@�t�C�K�̩M�D�K�̲ӭM�]�]�A�Pı���g���^�W���F�� 2 ������o�X�H�� 7,9�C�Pı���g�����P�ӧΦ��F�h������Pı��ê���ӭM�M���l��¦�A�Ҧp�C����o�B���g���ʪ��g�M�k�h�\���ê���Φ��C�����i�ܤF�@����s�����G�A�Ӭ�s���b�T�w�H���I�گ��g�` (hDRG) ���g���b�U�ر���U����o�커�ɪ���o�H�������g�������C�b�t���w�E肽�M�e�C���������g�� (IS) ���ɪ� hDRG ���g�����AIL-4 �M IL-13 ��۵o���g������ (SA) ���v�T�A�b�ϥΩM���ϥΨ�blasakimab �@���Pı���g���W�ӤƼҫ������p�U�i��F���q�C ���G �����������Ѫ��ƾ��ҹ�F eblasakimab ����� IL-4 �M IL-13 ��H�����g���ް_�����g���P�Ӫ����e���G�C���~�AIL-13 �� hDRG ���g����P�ǤW������肽 1-20 (PAMP20) �ӷP�A�ҩ��F�o�S���� MRGPRX2 ����b�H���Pı���g�������F�õo���@�ΡA���� 2 ���ӭM�]�l�b�h�زӭM�]�l�����W�j�@�λP��o�������e�f�C�b���g����U�AIL-4 �b hDRG ���g�������ɦ۵o���� (SA)�A�� eblasakimab ��ۭ��C�F�۵o���ʡC�o�i��O���g����U���g���ӷP�ʧ��ܪ������¦�C�o�Ǽƾڪ����AIL-13 �M IL-4 �i��b�v�T���g�����ʤ��o�����P���@�ΡA�Ө̥��Ԧ��ܳQ�ҩ��i�H���_�o��زӭM�]�l���@�ΡC ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking e-Posters at the 51st Annual European Society for Dermatological Research Meeting finance.yahoo.com/news/aslan-pharmaceuticals-presents-data-eblasakimab-110000948.html �X�Q�Ԫ��v�T�ڬw����g�٤����[ ���~�V�ѥi�������F �ڬw�ϥi�ण�}�Hwww.clinicaltrials.gov/ct2/show/NCT05158023 8��30�� 004 2b�w�}65�Ӥ���. 欧�{�ϥi�ण�}�H�@.ASLAN004 2b 16�g����� ASLAN004 VS��Ӳ�//�t��(������Ӳ�) IGA 0,1= 57% VS 15%//�t��42%(57%-15%=42%) �G.Tralokinumab �w��,�h�~12�� ��FDA ,��-��AD�����ĵ�(DUPILUMAB �᪺�@�ɲĤG��,DUPILUMAB). (�@).ECZTRA 1 Q2W//Q4W VS ��Ӳ� //������Ӳի� 2.EASI75 16�g 25%//-- VS 12.7%//12.3% (�G).ECZTRA 2 1.IGA 0,1 2.EASI75 pubmed.ncbi.nlm.nih.gov/33000465/ Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2) 1.At week 16, more patients who received tralokinumab vs. placebo achieved an IGA score of 0 or 1: and EASI 75: 25�P0% vs. 12�P7% (12�P1%, 95% CI 6�P5-17�P7; P < 0�P001) www.ncbi.nlm.nih.gov/pmc/articles/PMC7986411/ (�T)Tralokinumab 52�g�����v (1)ECZTRA 1 (2)ECZTRA 2 �b�ⶵ���� 52 �g�B�H���B�����B�w������Ӫ� III ������ ECZTRA 1 �M ECZTRA 2 ���A���צܭ��� AD �����H�Q�H�� (3:1) �����C 2 �g 300 mg �� tralokinumab �֤U�`�g�C Q2W�^�Φw�����C IGA ������ 0 �� 1 �M/�� EASI 75 ���w�� �b�� 16 �g�ϥ� tralokinumab ���w�̳Q���s�H�����t�� tralokinumab Q2W �ΨC 4 �g�@���Φw�����A���� 36 �g�C �o�Ǹ���w�b ClinicalTrials.gov ���U�GNCT03131648 �M NCT03160885�C In two 52‐week, randomized, double‐blind, placebo‐controlled, phase III trials, ECZTRA 1 and ECZTRA 2, adults with moderate‐to‐severe AD were randomized (3 : 1) to subcutaneous tralokinumab 300 mg every 2 weeks (Q2W) or placebo. Primary endpoints were Investigator��s Global Assessment (IGA) score of 0 or 1 at week 16 and ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16. Patients achieving an IGA score of 0 or 1 and/or EASI 75 with tralokinumab at week 16 were rerandomized to tralokinumab Q2W or every 4 weeks or placebo, for 36 weeks. The trials were registered with ClinicalTrials.gov: NCT03131648 and NCT03160885. �T.ASLAN004 2b ����� VS Tralokiumab 3��(16�g) ������Ӳ� 1.ASLAN004 2b ����� vs 2.Tralokiumab 3��(16�g)---������Ӳ� IGA 0,1= �t��8.7%~11.3%,����10%---C EASI75= �t��12.3%~20.8%,����16.6%---D 3.16�gPK �|:����ASLAN004 �����,�T���D�n���� IGA0,1 //EASI75 ��w�b��/�ڤW����Tralokiumab(�@�ɲĤG�W���w��) ASLAN004 AD�ĵ� �䤣��z�Ѯ�����. Dupilumab �T�� Q2W Leb. 40% �u��Dup. @% IGA. 41-22=19 EASI75 70-42=28 �G�BDupilumab +TCS 16�g�A�������组 �T�APK Leb./Dup. 结�� �[TCS��ALeb. �H�� Dup. �bIGA.�H22%, Leb.�QTCS �MLeb.AD2 �T��/16�g�q�İ�¦���۪�C Leb. AD2 16�g�C EASI75(%) pk�A�K�K�T���{�� 1.Dep.+TCS 16�g63.9//68.9//23.2 52�g/16�g=95%, �����h5% 2.Dup. SOLO 1/2 Q2W--% 16�g 51/44,����47.5 3.pk 68.9/47.5=145...16�g Dupilumab�Q TCS�A�b��16�g�۹�[TCS, �B52�g�u��5%. �G�BLebrikizumab �QTCS �T���{��x16�g�v���A 1.Leb.+TCS vs ���组 1.IGA0,1 41 vs 22 3.Leb.+TCS pK Lebrikizumab 1EASI76, 70/55=127%,�W�[27% Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, including INDIANAPOLIS, April 11, 2022 /PRNewswire/ -- At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company (NYSE: LLY) announced today at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. Lebrikizumab, an investigational IL-13 inhibitor, also showed improvements in itch, sleep interference, and quality of life when combined with TCS, compared to placebo plus TCS. Today��s ADhere data, together with results from the ADvocate monotherapy studies, demonstrate the potential for lebrikizumab to reduce disease burden and provide relief for people with uncontrolled atopic dermatitis when used either alone or combined with topicals, said Eric Simpson, M.D., M.C.R., Professor of Dermatology and Director of Clinical Research at Oregon Health & Science University in Portland, and principal investigator of ADhere. Lebrikizumab specifically targets the IL-13 pathway, which plays the central role in this chronic inflammatory disease. These results strengthen our understanding of lebrikizumab in atopic dermatitis and help establish it as a possible new treatment option. Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the interleukin 13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13R�\1/IL-4R�\ (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.1-5 IL-13 plays the central role in Type 2 inflammation in AD.6,7 In AD, IL-13 underlies the signs and symptoms including skin barrier dysfunction, itch, infection and hard, thickened areas of skin.8 Among patients taking lebrikizumab plus TCS, 41 percent achieved clear or almost clear skin (IGA) at 16 weeks compared to 22 percent of patients taking placebo plus TCS. At 16 weeks, 70 percent of patients taking lebrikizumab plus TCS achieved an EASI-75 response compared to 42 percent taking placebo plus TCS. Differences between patients receiving lebrikizumab in combination with TCS and placebo with TCS were observed as early as four weeks for EASI-75. �j������Lebrikizumab �T��52�g���ƾڰ�¦�T���̩w�q �O16�g�ɹF EASI75 ,�DEASI50(�@��AD �v���� Responders���w�q��EASI50)* Responders were defined as those achieving a 75% reduction in the Eczema Area and Severity Index from baseline (EASI-75) or an IGA 0 or 1 (clear or almost clear) with a 2-point improvement and without rescue medication use at Week 16. * �T���̩w�q����l���n�M�Y���{���Ʊq��u (EASI-75) ��� 75% �� IGA 0 �� 1�]���M�����Ρ��X�G�M�����^�A�ﵽ 2 ���B���i��ϴ����H �� 16 �g���Ī��ϥα��p�C Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly��s Phase 3 Monotherapy Atopic Dermatitis Trials finance.yahoo.com/news/lebrikizumab-dosed-every-four-weeks-121500944.html �@.Lebrikizumab 52�g���v���ĪG---�̰�u�Ĥ@�g���p��¦--------�j�ץ��p�U: 1�AAD1. IGA �G59%(EASI75)x74%//76% Vs 16�g���� 43%�A�g18��52�g�v������p����IGA 4%//2% EASI75: 59%(EASI75)x79%//79%% Vs 16�g���� 59%�A�g18��52�g�v������pEASI75,�˰h12%�C 2.AD2 IGA �G51%(EASI75)x81%//65% Vs 16�g���� 33%�g18��52�g�v������p����IGA 8%//0% EASI75: 51%�]EASI75)x85%//77% Vs 16�g���� 51%�g18��52�g�v������p �˰hEASI75 8%//12% ���סG�q16�g������52�g�M����IGA �ĪG ��������3.5%�A �@�@�@�@�@�@�@�@�@�@ Lebrikizumab Week 52 Results 1�PADvocate 1(�b��16�g��59%�FEASI75�^ Lebrikizumab 250 mg IGA (0,1) 74 %//76 % 2�PADvocate2�]�b��16�g51%�FEASI75�^ Pruritis (Itch) NRS 88 %//90 % Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2) |